<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer-Verlag</PublisherName>
    <PublisherLocation>New York</PublisherLocation>
  </PublisherInfo>
  <Journal>
    <JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered">
      <JournalID>12248</JournalID>
      <JournalElectronicISSN>1550-7416</JournalElectronicISSN>
      <JournalTitle>The AAPS Journal</JournalTitle>
      <JournalAbbreviatedTitle>AAPS J</JournalAbbreviatedTitle>
      <JournalSubjectGroup>
        <JournalSubject Code="F" Type="Primary">Pharmacy</JournalSubject>
        <JournalSubject Code="F00008" Priority="1" Type="Secondary">Pharmacy</JournalSubject>
        <JournalSubject Code="B21007" Priority="2" Type="Secondary">Pharmacology/Toxicology</JournalSubject>
        <JournalSubject Code="C12002" Priority="3" Type="Secondary">Biotechnology</JournalSubject>
      </JournalSubjectGroup>
    </JournalInfo>
    <Volume>
      <VolumeInfo TocLevels="0" VolumeType="Regular">
        <VolumeIDStart>7</VolumeIDStart>
        <VolumeIDEnd>7</VolumeIDEnd>
        <VolumeIssueCount>4</VolumeIssueCount>
      </VolumeInfo>
      <Issue IssueType="Regular">
        <IssueInfo TocLevels="0">
          <IssueIDStart>3</IssueIDStart>
          <IssueIDEnd>3</IssueIDEnd>
          <IssueArticleCount>25</IssueArticleCount>
          <IssueHistory>
            <CoverDate>
              <Year>2005</Year>
              <Month>9</Month>
            </CoverDate>
          </IssueHistory>
          <IssueCopyright>
            <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
            <CopyrightYear>2005</CopyrightYear>
          </IssueCopyright>
        </IssueInfo>
        <Article ID="Art11">
          <ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
            <ArticleID>73592</ArticleID>
            <ArticleDOI>10.1208/aapsj070361</ArticleDOI>
            <ArticleSequenceNumber>11</ArticleSequenceNumber>
            <ArticleTitle Language="En">k Opioids as potential treatments for stimulant dependence</ArticleTitle>
            <ArticleFirstPage>E592</ArticleFirstPage>
            <ArticleLastPage>E599</ArticleLastPage>
            <ArticleHistory>
              <RegistrationDate>
                <Year>2008</Year>
                <Month>1</Month>
                <Day>23</Day>
              </RegistrationDate>
              <Received>
                <Year>2005</Year>
                <Month>4</Month>
                <Day>22</Day>
              </Received>
              <Accepted>
                <Year>2005</Year>
                <Month>5</Month>
                <Day>30</Day>
              </Accepted>
            </ArticleHistory>
            <ArticleCopyright>
              <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
              <CopyrightYear>2005</CopyrightYear>
            </ArticleCopyright>
            <ArticleGrants Type="Regular">
              <MetadataGrant Grant="OpenAccess"/>
              <AbstractGrant Grant="OpenAccess"/>
              <BodyPDFGrant Grant="Restricted"/>
              <BodyHTMLGrant Grant="Restricted"/>
              <BibliographyGrant Grant="Restricted"/>
              <ESMGrant Grant="Restricted"/>
            </ArticleGrants>
            <ArticleContext>
              <JournalID>12248</JournalID>
              <VolumeIDStart>7</VolumeIDStart>
              <VolumeIDEnd>7</VolumeIDEnd>
              <IssueIDStart>3</IssueIDStart>
              <IssueIDEnd>3</IssueIDEnd>
            </ArticleContext>
          </ArticleInfo>
          <ArticleHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Thomas</GivenName>
                  <GivenName>E.</GivenName>
                  <FamilyName>Prisinzano</FamilyName>
                </AuthorName>
                <Contact>
                  <Phone>(319) 335-6920</Phone>
                  <Fax>(319) 335-8766</Fax>
                  <Email>thomas-prisinzano@uiowa.edu</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Kevin</GivenName>
                  <FamilyName>Tidgewell</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Wayne</GivenName>
                  <GivenName>W.</GivenName>
                  <FamilyName>Harding</FamilyName>
                </AuthorName>
              </Author>
              <Affiliation ID="Aff1">
                <OrgDivision>Division of Medicinal &amp; Natural Products Chemistry, College of Pharmacy</OrgDivision>
                <OrgName>The University of Iowa</OrgName>
                <OrgAddress>
                  <Postcode>52242</Postcode>
                  <City>Iowa City</City>
                  <State>Iowa</State>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1" Language="En">
              <Heading>Abstract</Heading>
              <Para>Stimulant abuse is a major problem in the United States and the development of pharmacological treatments for stimulant abuse remains an important therapeutic goal. Classically, the “dopamine hypothesis” has been used to explain the development of addiction and dependence of stimulants. This hypothesis involves the direct increase of dopamine as the major factor in mediating the abuse effects. Therefore, most treatments have focused on directly influencing the dopamine system. Another approach, which has been explored for potential treatments of stimulant abuse, is the use of κ opioid agonists. The κ receptor is known to be involved, via indirect effects, in synaptic dopamine levels. This review covers several classes of κ opioid ligands that have been explored for this purpose.</Para>
            </Abstract>
            <KeywordGroup Language="En">
              <Heading>Keywords</Heading>
              <Keyword>kappa</Keyword>
              <Keyword>opioid</Keyword>
              <Keyword>self-administration</Keyword>
              <Keyword>stimulant</Keyword>
            </KeywordGroup>
            <ArticleNote Type="Misc">
              <SimplePara>Published: October 19, 2005</SimplePara>
            </ArticleNote>
          </ArticleHeader>
          <BodyRef FileRef="BodyRef/PDF/12248_2008_Article_73592.pdf" TargetType="OnlinePDF"/>
          <ArticleBackmatter>
            <Bibliography ID="Bib1">
              <Heading>References</Heading>
              <Citation ID="CR1">
                <CitationNumber>1.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Cami</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Ferre</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Drug addiction</ArticleTitle>
                  <JournalTitle>N Engl J Med</JournalTitle>
                  <VolumeID>349</VolumeID>
                  <FirstPage>975</FirstPage>
                  <LastPage>986</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12954747</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXntFeitrg%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1056/NEJMra023160</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Cami J, Ferre M. Drug addiction.<Emphasis Type="Italic">N Engl J Med</Emphasis>. 2003;349:975–986.</BibUnstructured>
              </Citation>
              <Citation ID="CR2">
                <CitationNumber>2.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>EJ</Initials>
                    <FamilyName>Nestler</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Molecular basis of long-term plasticity underlying addiction</ArticleTitle>
                  <JournalTitle>Nat Rev Neurosci</JournalTitle>
                  <VolumeID>2</VolumeID>
                  <FirstPage>119</FirstPage>
                  <LastPage>128</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11252991</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXisl2qu78%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/35053570</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Nestler EJ. Molecular basis of long-term plasticity underlying addiction.<Emphasis Type="Italic">Nat Rev Neurosci</Emphasis>. 2001;2:119–128.</BibUnstructured>
              </Citation>
              <Citation ID="CR3">
                <CitationNumber>3.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>LA</Initials>
                    <FamilyName>Mitscher</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W</Initials>
                    <FamilyName>Baker</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Tuberculosis: a search for novel therapy starting with natural products</ArticleTitle>
                  <JournalTitle>Med Res Rev</JournalTitle>
                  <VolumeID>18</VolumeID>
                  <FirstPage>363</FirstPage>
                  <LastPage>374</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9828037</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXnsFGjsr0%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/(SICI)1098-1128(199811)18:6&lt;363::AID-MED1&gt;3.0.CO;2-I</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mitscher LA, Baker W. Tuberculosis: a search for novel therapy starting with natural products.<Emphasis Type="Italic">Med Res Rev</Emphasis>. 1998;18:363–374.</BibUnstructured>
              </Citation>
              <Citation ID="CR4">
                <CitationNumber>4.</CitationNumber>
                <BibBook>
                  <BibAuthorName>
                    <Initials>CB</Initials>
                    <FamilyName>McCoy</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JA</Initials>
                    <FamilyName>Inciardi</FamilyName>
                  </BibAuthorName>
                  <Year>1995</Year>
                  <BookTitle>Sex, Drugs, and the Continuing, Spread of AIDS</BookTitle>
                  <PublisherName>Roxbury Publishing Co</PublisherName>
                  <PublisherLocation>Los Angeles</PublisherLocation>
                </BibBook>
                <BibUnstructured>McCoy CB, Inciardi JA.<Emphasis Type="Italic">Sex, Drugs, and the Continuing, Spread of AIDS</Emphasis>. Los Angeles: Roxbury Publishing Co; 1995.</BibUnstructured>
              </Citation>
              <Citation ID="CR5">
                <CitationNumber>5.</CitationNumber>
                <BibBook>
                  <InstitutionalAuthorName>National Drug Intelligence Center</InstitutionalAuthorName>
                  <Year>2004</Year>
                  <BookTitle>National Drug Threat Assessment 2004</BookTitle>
                  <PublisherName>US Department of Justice</PublisherName>
                  <PublisherLocation>Washington, DC</PublisherLocation>
                </BibBook>
                <BibUnstructured>National Drug Intelligence Center.<Emphasis Type="Italic">National Drug Threat Assessment 2004</Emphasis>. Washington, DC: US Department of Justice; 2004.</BibUnstructured>
              </Citation>
              <Citation ID="CR6">
                <CitationNumber>6.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>LL</Initials>
                    <FamilyName>Howell</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KM</Initials>
                    <FamilyName>Wilcox</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">The dopamine transporter and cocaine medication development: drug self-administration, in nonhuman primates</ArticleTitle>
                  <JournalTitle>J Pharmacol Exp Ther</JournalTitle>
                  <VolumeID>298</VolumeID>
                  <FirstPage>1</FirstPage>
                  <LastPage>6</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11408518</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXksFCht78%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Howell LL, Wilcox KM. The dopamine transporter and cocaine medication development: drug self-administration, in nonhuman primates.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2001;298:1–6.</BibUnstructured>
              </Citation>
              <Citation ID="CR7">
                <CitationNumber>7.</CitationNumber>
                <BibBook>
                  <BibAuthorName>
                    <Initials>DI</Initials>
                    <FamilyName>National</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <BookTitle>C. National Drug Threat, Assessment</BookTitle>
                  <PublisherName>US Department of Justice</PublisherName>
                  <PublisherLocation>Johnston, PA</PublisherLocation>
                </BibBook>
                <BibUnstructured>National DI.<Emphasis Type="Italic">C. National Drug Threat, Assessment</Emphasis>. Johnston, PA: US Department of Justice; 2001.</BibUnstructured>
              </Citation>
              <Citation ID="CR8">
                <CitationNumber>8.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>MD</Initials>
                    <FamilyName>Anglin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Burke</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Perrochet</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Stamper</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Dawud-Noursi</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">History of the methamphetamine problem</ArticleTitle>
                  <JournalTitle>J Psychoactive Drugs</JournalTitle>
                  <VolumeID>32</VolumeID>
                  <FirstPage>137</FirstPage>
                  <LastPage>141</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10908000</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD3M%2FjvVGgsQ%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Anglin MD, Burke C, Perrochet B, Stamper E, Dawud-Noursi S. History of the methamphetamine problem.<Emphasis Type="Italic">J Psychoactive Drugs</Emphasis>. 2000;32:137–141.</BibUnstructured>
              </Citation>
              <Citation ID="CR9">
                <CitationNumber>9.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>RA</Initials>
                    <FamilyName>Rawson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MD</Initials>
                    <FamilyName>Anglin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W</Initials>
                    <FamilyName>Ling</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Will the methamphetamine problem go away?</ArticleTitle>
                  <JournalTitle>J Addict Dis</JournalTitle>
                  <VolumeID>21</VolumeID>
                  <FirstPage>5</FirstPage>
                  <LastPage>19</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11831500</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1300/J069v21n01_02</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Rawson RA, Anglin MD, Ling W. Will the methamphetamine problem go away?.<Emphasis Type="Italic">J Addict Dis</Emphasis>. 2002;21:5–19.</BibUnstructured>
              </Citation>
              <Citation ID="CR10">
                <CitationNumber>10.</CitationNumber>
                <BibUnstructured>Rood L. 2005.</BibUnstructured>
              </Citation>
              <Citation ID="CR11">
                <CitationNumber>11.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>FI</Initials>
                    <FamilyName>Carroll</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LL</Initials>
                    <FamilyName>Howell</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MJ</Initials>
                    <FamilyName>Kuhar</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Pharmacotherapies for treatment of cocaine abuse preclinical aspects</ArticleTitle>
                  <JournalTitle>J Med Chem</JournalTitle>
                  <VolumeID>42</VolumeID>
                  <FirstPage>2721</FirstPage>
                  <LastPage>2736</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10425082</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXkt1Sjs7c%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1021/jm9706729</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Carroll FI, Howell LL, Kuhar, MJ. Pharmacotherapies for treatment of cocaine abuse preclinical aspects.<Emphasis Type="Italic">J Med Chem</Emphasis>. 1999;42:2721–2736.</BibUnstructured>
              </Citation>
              <Citation ID="CR12">
                <CitationNumber>12.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>MJ</Initials>
                    <FamilyName>Kuhar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MC</Initials>
                    <FamilyName>Ritz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JW</Initials>
                    <FamilyName>Boja</FamilyName>
                  </BibAuthorName>
                  <Year>1991</Year>
                  <ArticleTitle Language="En">The dopamine hypothesis of the reinforcing properties of cocaine</ArticleTitle>
                  <JournalTitle>Trends Neurosci</JournalTitle>
                  <VolumeID>14</VolumeID>
                  <FirstPage>299</FirstPage>
                  <LastPage>302</LastPage>
                  <Occurrence Type="PID">
                    <Handle>1719677</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK3MXlvFOnu7k%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0166-2236(91)90141-G</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kuhar MJ, Ritz MC, Boja JW. The dopamine hypothesis of the reinforcing properties of cocaine.<Emphasis Type="Italic">Trends Neurosci</Emphasis>. 1991;14:299–302.</BibUnstructured>
              </Citation>
              <Citation ID="CR13">
                <CitationNumber>13.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>GF</Initials>
                    <FamilyName>Koob</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>FE</Initials>
                    <FamilyName>Bloom</FamilyName>
                  </BibAuthorName>
                  <Year>1988</Year>
                  <ArticleTitle Language="En">Cellular and molecular mechanisms of drug dependence</ArticleTitle>
                  <JournalTitle>Science</JournalTitle>
                  <VolumeID>242</VolumeID>
                  <FirstPage>715</FirstPage>
                  <LastPage>723</LastPage>
                  <Occurrence Type="PID">
                    <Handle>2903550</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL1MXhsl2itA%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1126/science.2903550</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence.<Emphasis Type="Italic">Science</Emphasis>. 1988;242:715–723.</BibUnstructured>
              </Citation>
              <Citation ID="CR14">
                <CitationNumber>14.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>TE</Initials>
                    <FamilyName>Robinson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KC</Initials>
                    <FamilyName>Berridge</FamilyName>
                  </BibAuthorName>
                  <Year>1993</Year>
                  <ArticleTitle Language="En">The neural basis of drug craving: an incentive-sensitization theory of addiction</ArticleTitle>
                  <JournalTitle>Brain Res Brain Res Rev</JournalTitle>
                  <VolumeID>18</VolumeID>
                  <FirstPage>247</FirstPage>
                  <LastPage>291</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8401595</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK3sXlsFWnu78%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0165-0173(93)90013-P</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction.<Emphasis Type="Italic">Brain Res Brain Res Rev</Emphasis>. 1993;18:247–291.</BibUnstructured>
              </Citation>
              <Citation ID="CR15">
                <CitationNumber>15.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>MJ</Initials>
                    <FamilyName>Kuhar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>NS</Initials>
                    <FamilyName>Pilotte</FamilyName>
                  </BibAuthorName>
                  <Year>1996</Year>
                  <ArticleTitle Language="En">Neurochemical changes in cocaine withdrawal</ArticleTitle>
                  <JournalTitle>Trends Pharmacol Sci</JournalTitle>
                  <VolumeID>17</VolumeID>
                  <FirstPage>260</FirstPage>
                  <LastPage>264</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8756185</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK28Xks1eisrk%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0165-6147(96)10024-9</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kuhar MJ, Pilotte NS. Neurochemical changes in cocaine withdrawal.<Emphasis Type="Italic">Trends Pharmacol Sci</Emphasis>. 1996;17:260–264.</BibUnstructured>
              </Citation>
              <Citation ID="CR16">
                <CitationNumber>16.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>PM</Initials>
                    <FamilyName>Callahan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KA</Initials>
                    <FamilyName>Cunningham</FamilyName>
                  </BibAuthorName>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">Modulation of the discriminative stimulus properties of cocaine: comparison of the effects of fluoxetine with 5-HT1A and 5-HT1B receptor, agonists</ArticleTitle>
                  <JournalTitle>Neuropharmacology</JournalTitle>
                  <VolumeID>36</VolumeID>
                  <FirstPage>373</FirstPage>
                  <LastPage>381</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9175616</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2sXjtlOmsbs%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0028-3908(97)00010-5</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Callahan PM, Cunningham KA. Modulation of the discriminative stimulus properties of cocaine: comparison of the effects of fluoxetine with 5-HT1A and 5-HT1B receptor, agonists.<Emphasis Type="Italic">Neuropharmacology</Emphasis>. 1997;36:373–381.</BibUnstructured>
              </Citation>
              <Citation ID="CR17">
                <CitationNumber>17.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>PM</Initials>
                    <FamilyName>Callahan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KA</Initials>
                    <FamilyName>Cunningham</FamilyName>
                  </BibAuthorName>
                  <Year>1995</Year>
                  <ArticleTitle Language="En">Modulation of the discriminative stimulus properties of cocaine by 5-HT1B and 5-HT2C receptors</ArticleTitle>
                  <JournalTitle>J Pharmacol Exp Ther</JournalTitle>
                  <VolumeID>274</VolumeID>
                  <FirstPage>1414</FirstPage>
                  <LastPage>1424</LastPage>
                  <Occurrence Type="PID">
                    <Handle>7562516</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2MXot1yjtrc%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Callahan PM, Cunningham KA. Modulation of the discriminative stimulus properties of cocaine by 5-HT1B and 5-HT2C receptors.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 1995;274:1414–1424.</BibUnstructured>
              </Citation>
              <Citation ID="CR18">
                <CitationNumber>18.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>LR</Initials>
                    <FamilyName>McMahon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KA</Initials>
                    <FamilyName>Cunningham</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Antagonism of 5-Hydroxytryptamine2A receptors attenuates the behavioral effects of cocaine in rats</ArticleTitle>
                  <JournalTitle>J Pharmacol Exp Ther</JournalTitle>
                  <VolumeID>297</VolumeID>
                  <FirstPage>357</FirstPage>
                  <LastPage>363</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11259563</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXisVSrtrY%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>McMahon LR, Cunningham KA. Antagonism of 5-Hydroxytryptamine2A receptors attenuates the behavioral effects of cocaine in rats.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2001;297:357–363.</BibUnstructured>
              </Citation>
              <Citation ID="CR19">
                <CitationNumber>19.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AE</Initials>
                    <FamilyName>Kelley</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CG</Initials>
                    <FamilyName>Lang</FamilyName>
                  </BibAuthorName>
                  <Year>1989</Year>
                  <ArticleTitle Language="En">Effects of GBR 12909, a selective dopamine uptake inhibitor, on motor activity and operant behavior in the rat</ArticleTitle>
                  <JournalTitle>Eur J Pharmacol</JournalTitle>
                  <VolumeID>167</VolumeID>
                  <FirstPage>385</FirstPage>
                  <LastPage>395</LastPage>
                  <Occurrence Type="PID">
                    <Handle>2530095</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL1MXlvVOgsbg%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0014-2999(89)90447-0</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kelley AE, Lang CG. Effects of GBR 12909, a selective dopamine uptake inhibitor, on motor activity and operant behavior in the rat.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 1989;167:385–395.</BibUnstructured>
              </Citation>
              <Citation ID="CR20">
                <CitationNumber>20.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>FI</Initials>
                    <FamilyName>Carroll</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Kotian</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Dehghani</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1995</Year>
                  <ArticleTitle Language="En">Cocaine and 3β-(4′-Substituted phenyl)tropane-2β-carboxylic acid ester and amide analogues. New high-affinity and selective compounds for the dopamine transporter</ArticleTitle>
                  <JournalTitle>J Med Chem</JournalTitle>
                  <VolumeID>38</VolumeID>
                  <FirstPage>379</FirstPage>
                  <LastPage>388</LastPage>
                  <Occurrence Type="PID">
                    <Handle>7830281</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2MXivFOqtb4%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1021/jm00002a020</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Carroll FI, Kotian P, Dehghani A, et al. Cocaine and 3β-(4′-Substituted phenyl)tropane-2β-carboxylic acid ester and amide analogues. New high-affinity and selective compounds for the dopamine transporter.<Emphasis Type="Italic">J Med Chem</Emphasis>. 1995;38:379–388.</BibUnstructured>
              </Citation>
              <Citation ID="CR21">
                <CitationNumber>21.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Belej</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Manji</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Sioutis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HM</Initials>
                    <FamilyName>Barros</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JN</Initials>
                    <FamilyName>Nobrega</FamilyName>
                  </BibAuthorName>
                  <Year>1996</Year>
                  <ArticleTitle Language="En">Changes in serotonin and norepinephrine uptake sites after chronic cocaine: pre- vs post-withdrawal effects</ArticleTitle>
                  <JournalTitle>Brain Res</JournalTitle>
                  <VolumeID>736</VolumeID>
                  <FirstPage>287</FirstPage>
                  <LastPage>296</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8930335</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK28XmtV2js7w%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0006-8993(96)00713-5</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Belej T, Manji D, Sioutis S, Barros HM, Nobrega JN. Changes in serotonin and norepinephrine uptake sites after chronic cocaine: pre- vs post-withdrawal effects.<Emphasis Type="Italic">Brain Res</Emphasis>. 1996;736:287–296.</BibUnstructured>
              </Citation>
              <Citation ID="CR22">
                <CitationNumber>22.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Sora</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>FS</Initials>
                    <FamilyName>Hall</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AM</Initials>
                    <FamilyName>Andrews</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">MOlecular mechanisms of cocaine reward. Combined dopamine and serotonin transporter knockouts eliminate cocaine place preference</ArticleTitle>
                  <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                  <VolumeID>98</VolumeID>
                  <FirstPage>5300</FirstPage>
                  <LastPage>5305</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11320258</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXjt1Ontr0%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1073/pnas.091039298</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Sora I, Hall FS, Andrews AM, et al. MOlecular mechanisms of cocaine reward. Combined dopamine and serotonin transporter knockouts eliminate cocaine place preference.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 2001;98:5300–5305.</BibUnstructured>
              </Citation>
              <Citation ID="CR23">
                <CitationNumber>23.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>MH</Initials>
                    <FamilyName>Baumann</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RB</Initials>
                    <FamilyName>Rothman</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Alterations in serotonergic responsiveness during cocaine withdrawal in rats: similarities to major depression in humans</ArticleTitle>
                  <JournalTitle>Biol Psychiatry</JournalTitle>
                  <VolumeID>44</VolumeID>
                  <FirstPage>578</FirstPage>
                  <LastPage>591</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9787882</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXmvFWksb0%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0006-3223(98)00123-1</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Baumann MH, Rothman RB. Alterations in serotonergic responsiveness during cocaine withdrawal in rats: similarities to major depression in humans.<Emphasis Type="Italic">Biol Psychiatry</Emphasis>. 1998;44:578–591.</BibUnstructured>
              </Citation>
              <Citation ID="CR24">
                <CitationNumber>24.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>RB</Initials>
                    <FamilyName>Rothman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MH</Initials>
                    <FamilyName>Baumann</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CM</Initials>
                    <FamilyName>Dersch</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin</ArticleTitle>
                  <JournalTitle>Synapse</JournalTitle>
                  <VolumeID>39</VolumeID>
                  <FirstPage>32</FirstPage>
                  <LastPage>41</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11071707</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXovFahsLg%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/1098-2396(20010101)39:1&lt;32::AID-SYN5&gt;3.0.CO;2-3</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.<Emphasis Type="Italic">Synapse</Emphasis>. 2001;39:32–41.</BibUnstructured>
              </Citation>
              <Citation ID="CR25">
                <CitationNumber>25.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SS</Initials>
                    <FamilyName>Kulkarni</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AH</Initials>
                    <FamilyName>Newman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WJ</Initials>
                    <FamilyName>Houlihan</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Three-dimensional quantitative structure-activity relationships of mazindol analogues at the dopamine transporter</ArticleTitle>
                  <JournalTitle>J Med Chem</JournalTitle>
                  <VolumeID>45</VolumeID>
                  <FirstPage>4119</FirstPage>
                  <LastPage>4127</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12213055</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XntlKjug%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1021/jm0102093</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kulkarni SS, Newman AH, Houlihan WJ. Three-dimensional quantitative structure-activity relationships of mazindol analogues at the dopamine transporter.<Emphasis Type="Italic">J Med Chem</Emphasis>. 2002;45:4119–4127.</BibUnstructured>
              </Citation>
              <Citation ID="CR26">
                <CitationNumber>26.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>MJ</Initials>
                    <FamilyName>Kreek</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KS</Initials>
                    <FamilyName>LaForge</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Butelman</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Pharmacotherapy of addictions</ArticleTitle>
                  <JournalTitle>Nat Rev Drug Discov</JournalTitle>
                  <VolumeID>1</VolumeID>
                  <FirstPage>710</FirstPage>
                  <LastPage>726</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12209151</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XmslamtL4%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/nrd897</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kreek MJ, LaForge KS, Butelman E. Pharmacotherapy of addictions.<Emphasis Type="Italic">Nat Rev Drug Discov</Emphasis>. 2002;1:710–726.</BibUnstructured>
              </Citation>
              <Citation ID="CR27">
                <CitationNumber>27.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Prisinzano</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KC</Initials>
                    <FamilyName>Rice</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MH</Initials>
                    <FamilyName>Baumann</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RB</Initials>
                    <FamilyName>Rothman</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Development of neurochemical normalization (“agonist substitution”) therapeutics for stimulant, abuse: focus on the dopamine uptake inhibitor, GBR 12909</ArticleTitle>
                  <JournalTitle>Curr Med Chem CNS Agents</JournalTitle>
                  <VolumeID>4</VolumeID>
                  <FirstPage>47</FirstPage>
                  <LastPage>59</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXjt1elsrw%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Prisinzano T, Rice KC, Baumann MH, Rothman RB. Development of neurochemical normalization (“agonist substitution”) therapeutics for stimulant, abuse: focus on the dopamine uptake inhibitor, GBR 12909.<Emphasis Type="Italic">Curr Med Chem CNS Agents</Emphasis>. 2004;4:47–59.</BibUnstructured>
              </Citation>
              <Citation ID="CR28">
                <CitationNumber>28.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Grabowski</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Shearer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Merrill</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SS</Initials>
                    <FamilyName>Negus</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence</ArticleTitle>
                  <JournalTitle>Addict Behav</JournalTitle>
                  <VolumeID>29</VolumeID>
                  <FirstPage>1439</FirstPage>
                  <LastPage>1464</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15345275</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.addbeh.2004.06.018</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Grabowski J, Shearer J, Merrill J, Negus SS. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence.<Emphasis Type="Italic">Addict Behav</Emphasis>. 2004;29:1439–1464.</BibUnstructured>
              </Citation>
              <Citation ID="CR29">
                <CitationNumber>29.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>NK</Initials>
                    <FamilyName>Mello</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SS</Initials>
                    <FamilyName>Negus</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Interactions between kappa opioid, agonists and cocaine. Preclinical studies</ArticleTitle>
                  <JournalTitle>Ann N Y Acad Sci</JournalTitle>
                  <VolumeID>909</VolumeID>
                  <FirstPage>104</FirstPage>
                  <LastPage>132</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10911926</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXlsVOjtLg%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1749-6632.2000.tb06678.x</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mello NK, Negus SS. Interactions between kappa opioid, agonists and cocaine. Preclinical studies.<Emphasis Type="Italic">Ann N Y Acad Sci</Emphasis>. 2000;909:104–132.</BibUnstructured>
              </Citation>
              <Citation ID="CR30">
                <CitationNumber>30.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>TS</Initials>
                    <FamilyName>Shippenberg</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>VI</Initials>
                    <FamilyName>Chefer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Zapata</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CA</Initials>
                    <FamilyName>Heidbreder</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Modulation of the behavioral and neurochemical effects of psychostimulants by kappa-opioid receptor systems</ArticleTitle>
                  <JournalTitle>Ann NY Acad Sci</JournalTitle>
                  <VolumeID>937</VolumeID>
                  <FirstPage>50</FirstPage>
                  <LastPage>73</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11458540</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXlsV2ku7Y%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1749-6632.2001.tb03558.x</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Shippenberg TS, Chefer VI, Zapata A, Heidbreder CA. Modulation of the behavioral and neurochemical effects of psychostimulants by kappa-opioid receptor systems.<Emphasis Type="Italic">Ann NY Acad Sci</Emphasis>. 2001;937:50–73.</BibUnstructured>
              </Citation>
              <Citation ID="CR31">
                <CitationNumber>31.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SL</Initials>
                    <FamilyName>Collins</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PM</Initials>
                    <FamilyName>Kunko</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Ladenheim</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Chronic cocaine increases kappa-opioid receptor density: lack of effect by selective dopamine uptake inhibitors</ArticleTitle>
                  <JournalTitle>Synapse</JournalTitle>
                  <VolumeID>45</VolumeID>
                  <FirstPage>153</FirstPage>
                  <LastPage>158</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12112394</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XmtVegsbk%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/syn.10091</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Collins SL, Kunko PM, Ladenheim B, et al. Chronic cocaine increases kappa-opioid receptor density: lack of effect by selective dopamine uptake inhibitors.<Emphasis Type="Italic">Synapse</Emphasis>. 2002;45:153–158.</BibUnstructured>
              </Citation>
              <Citation ID="CR32">
                <CitationNumber>32.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JA</Initials>
                    <FamilyName>Tzaferis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JF</Initials>
                    <FamilyName>McGinty</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Kappa opioid receptor stimulation decreases amphetamine-induced behavior and neuropeptide mRNA expression in the striatum</ArticleTitle>
                  <JournalTitle>Brain Res Mol Brain Res</JournalTitle>
                  <VolumeID>93</VolumeID>
                  <FirstPage>27</FirstPage>
                  <LastPage>35</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11532335</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXmt1yhurY%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0169-328X(01)00178-4</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Tzaferis JA, McGinty JF. Kappa opioid receptor stimulation decreases amphetamine-induced behavior and neuropeptide mRNA expression in the striatum.<Emphasis Type="Italic">Brain Res Mol Brain Res</Emphasis>. 2001;93:27–35.</BibUnstructured>
              </Citation>
              <Citation ID="CR33">
                <CitationNumber>33.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>McCarthy</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Wetzel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JK</Initials>
                    <FamilyName>Sliker</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TK</Initials>
                    <FamilyName>Eisenstein</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TJ</Initials>
                    <FamilyName>Rogers</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Opioids, opioid receptors, and the immune response</ArticleTitle>
                  <JournalTitle>Drug Alcohol Depend.</JournalTitle>
                  <VolumeID>62</VolumeID>
                  <FirstPage>111</FirstPage>
                  <LastPage>123</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11245967</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXhs1Cju78%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0376-8716(00)00181-2</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>McCarthy L, Wetzel M, Sliker JK, Eisenstein TK, Rogers TJ. Opioids, opioid receptors, and the immune response.<Emphasis Type="Italic">Drug Alcohol Depend.</Emphasis> 2001;62:111–123.</BibUnstructured>
              </Citation>
              <Citation ID="CR34">
                <CitationNumber>34.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>CC</Initials>
                    <FamilyName>Chao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Gekker</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Hu</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1996</Year>
                  <ArticleTitle Language="En">Kappa opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression</ArticleTitle>
                  <JournalTitle>Proc, Natl Acad Sci USA</JournalTitle>
                  <VolumeID>93</VolumeID>
                  <FirstPage>8051</FirstPage>
                  <LastPage>8056</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK28XksFSru7k%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1073/pnas.93.15.8051</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Chao CC, Gekker G, Hu S, et al. Kappa opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression.<Emphasis Type="Italic">Proc, Natl Acad Sci USA</Emphasis>. 1996;93:8051–8056.</BibUnstructured>
              </Citation>
              <Citation ID="CR35">
                <CitationNumber>35.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>PK</Initials>
                    <FamilyName>Peterson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Gekker</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JR</Initials>
                    <FamilyName>Lokensgard</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Kappa opioid receptor agonist suppression of HIV-1 expression in CD4+ lymphocytes</ArticleTitle>
                  <JournalTitle>Biochem Pharmacol</JournalTitle>
                  <VolumeID>61</VolumeID>
                  <FirstPage>1145</FirstPage>
                  <LastPage>1151</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11301048</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXisF2qt7w%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0006-2952(01)00574-3</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Peterson PK, Gekker G, Lokensgard JR, et al. Kappa opioid receptor agonist suppression of HIV-1 expression in CD4+ lymphocytes.<Emphasis Type="Italic">Biochem Pharmacol</Emphasis>. 2001;61: 1145–1151.</BibUnstructured>
              </Citation>
              <Citation ID="CR36">
                <CitationNumber>36.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>G.</Initials>
                    <FamilyName>Gekker</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Hu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MP</Initials>
                    <FamilyName>Wentland</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">κ-Opioid receptor ligands inhibit cocaine-induced HIV-1 expression in microglial cells</ArticleTitle>
                  <JournalTitle>J Pharmacol Exp Ther</JournalTitle>
                  <VolumeID>309</VolumeID>
                  <FirstPage>600</FirstPage>
                  <LastPage>606</LastPage>
                  <Occurrence Type="PID">
                    <Handle>14757849</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXjs1yhurk%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1124/jpet.103.060160</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Gekker G., Hu S, Wentland MP, et al. κ-Opioid receptor ligands inhibit cocaine-induced HIV-1 expression in microglial cells.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2004;309:600–606.</BibUnstructured>
              </Citation>
              <Citation ID="CR37">
                <CitationNumber>37.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Werling</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Frattali</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Portoghese</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Takemori</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Cox</FamilyName>
                  </BibAuthorName>
                  <Year>1988</Year>
                  <ArticleTitle Language="En">Kappa receptor regulation of dopamine release from striatum and cortex of rats and guinea pigs</ArticleTitle>
                  <JournalTitle>J Pharmacol Exp Ther</JournalTitle>
                  <VolumeID>246</VolumeID>
                  <FirstPage>282</FirstPage>
                  <LastPage>286</LastPage>
                  <Occurrence Type="PID">
                    <Handle>2839666</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL1cXlt1aqsL8%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Werling L, Frattali A, Portoghese P, Takemori A, Cox B. Kappa receptor regulation of dopamine release from striatum and cortex of rats and guinea pigs.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 1988;246:282–286.</BibUnstructured>
              </Citation>
              <Citation ID="CR38">
                <CitationNumber>38.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Chiara</FamilyName>
                    <Particle>Di</Particle>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Imperato</FamilyName>
                  </BibAuthorName>
                  <Year>1988</Year>
                  <ArticleTitle Language="En">Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats</ArticleTitle>
                  <JournalTitle>J Pharmacol Exp Ther</JournalTitle>
                  <VolumeID>244</VolumeID>
                  <FirstPage>1067</FirstPage>
                  <LastPage>1080</LastPage>
                  <Occurrence Type="PID">
                    <Handle>2855239</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Di Chiara G, Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 1988;244:1067–1080.</BibUnstructured>
              </Citation>
              <Citation ID="CR39">
                <CitationNumber>39.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Chiara</FamilyName>
                    <Particle>Di</Particle>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Imperato</FamilyName>
                  </BibAuthorName>
                  <Year>1988</Year>
                  <ArticleTitle Language="En">Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats</ArticleTitle>
                  <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                  <VolumeID>85</VolumeID>
                  <FirstPage>5274</FirstPage>
                  <LastPage>5278</LastPage>
                  <Occurrence Type="PID">
                    <Handle>2899326</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1073/pnas.85.14.5274</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1988;85:5274–5278.</BibUnstructured>
              </Citation>
              <Citation ID="CR40">
                <CitationNumber>40.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Spanagel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Herz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TS</Initials>
                    <FamilyName>Shippenberg</FamilyName>
                  </BibAuthorName>
                  <Year>1990</Year>
                  <ArticleTitle Language="En">The effects of opioid, peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study</ArticleTitle>
                  <JournalTitle>J Neurochem</JournalTitle>
                  <VolumeID>55</VolumeID>
                  <FirstPage>1734</FirstPage>
                  <LastPage>1740</LastPage>
                  <Occurrence Type="PID">
                    <Handle>1976759</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK3cXmtVGis7c%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1471-4159.1990.tb04963.x</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Spanagel R, Herz A, Shippenberg TS. The effects of opioid, peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study.<Emphasis Type="Italic">J Neurochem</Emphasis>. 1990;55:1734–1740.</BibUnstructured>
              </Citation>
              <Citation ID="CR41">
                <CitationNumber>41.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Spanagel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Herz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Shippenberg</FamilyName>
                  </BibAuthorName>
                  <Year>1992</Year>
                  <ArticleTitle Language="En">Opposing tonically active endogenous opioid, systems modulate the mesolimbic dopaminergic pathway</ArticleTitle>
                  <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                  <VolumeID>89</VolumeID>
                  <FirstPage>2046</FirstPage>
                  <LastPage>2050</LastPage>
                  <Occurrence Type="PID">
                    <Handle>1347943</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK38XisVyrtbc%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1073/pnas.89.6.2046</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Spanagel R, Herz A, Shippenberg T. Opposing tonically active endogenous opioid, systems modulate the mesolimbic dopaminergic pathway.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1992;89:2046–2050.</BibUnstructured>
              </Citation>
              <Citation ID="CR42">
                <CitationNumber>42.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Jackisch</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Hotz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Hertting</FamilyName>
                  </BibAuthorName>
                  <Year>1993</Year>
                  <ArticleTitle Language="En">No evidence for presynaptic opioid receptors on cholinergic, but presence of kappa-receptors on dopaminergic neurons in the rabbit caudate nucleus: involvement of endogenous opioids</ArticleTitle>
                  <JournalTitle>Naunyn Schmiedebergs Arch Pharmacol</JournalTitle>
                  <VolumeID>348</VolumeID>
                  <FirstPage>234</FirstPage>
                  <LastPage>241</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8232601</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK2c%2FltVajsQ%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/BF00169150</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Jackisch R, Hotz H, Hertting G. No evidence for presynaptic opioid receptors on cholinergic, but presence of kappa-receptors on dopaminergic neurons in the rabbit caudate nucleus: involvement of endogenous opioids.<Emphasis Type="Italic">Naunyn Schmiedebergs Arch Pharmacol</Emphasis>. 1993;348:234–241.</BibUnstructured>
              </Citation>
              <Citation ID="CR43">
                <CitationNumber>43.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>EB</Initials>
                    <FamilyName>Margolis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GO</Initials>
                    <FamilyName>Hjelmstad</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Bonci</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HL</Initials>
                    <FamilyName>Fields</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">κ-Opioid agonists directly inhibit midbrain dopaminergic neurons</ArticleTitle>
                  <JournalTitle>J Neurosci</JournalTitle>
                  <VolumeID>23</VolumeID>
                  <FirstPage>9981</FirstPage>
                  <LastPage>9986</LastPage>
                  <Occurrence Type="PID">
                    <Handle>14602811</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXovFClsrs%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Margolis EB, Hjelmstad GO, Bonci A, Fields HL. κ-Opioid agonists directly inhibit midbrain dopaminergic neurons.<Emphasis Type="Italic">J Neurosci</Emphasis>. 2003;23:9981–9986.</BibUnstructured>
              </Citation>
              <Citation ID="CR44">
                <CitationNumber>44.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Suzuki</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Kishimoto</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Ozaki</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Narita</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Mechanism of opioid dependence and interaction between opioid receptors</ArticleTitle>
                  <JournalTitle>Eur J Pain</JournalTitle>
                  <VolumeID>5</VolumeID>
                  <FirstPage>63</FirstPage>
                  <LastPage>65</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11798220</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XhtFWrtLY%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1053/eujp.2001.0282</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Suzuki T, Kishimoto Y, Ozaki S, Narita M. Mechanism of opioid dependence and interaction between opioid receptors.<Emphasis Type="Italic">Eur J Pain</Emphasis>. 2001;5:63–65.</BibUnstructured>
              </Citation>
              <Citation ID="CR45">
                <CitationNumber>45.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AC</Initials>
                    <FamilyName>Thompson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Zapata</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JB</Initials>
                    <FamilyName>Justice</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">κ-Opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine</ArticleTitle>
                  <JournalTitle>J Neurosci</JournalTitle>
                  <VolumeID>20</VolumeID>
                  <FirstPage>9333</FirstPage>
                  <LastPage>9340</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11125013</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXis1WmsQ%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Thompson AC Jr, Zapata A, Jr, Justice JB Jr, et al. κ-Opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine.<Emphasis Type="Italic">J Neurosci</Emphasis>. 2000;20:9333–9340.</BibUnstructured>
              </Citation>
              <Citation ID="CR46">
                <CitationNumber>46.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Izenwasser</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>French</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>FI</Initials>
                    <FamilyName>Carroll</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PM</Initials>
                    <FamilyName>Funko</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Continuous infusion of selective dopamine uptake inhibitors or cocaine produces time-dependent changes in rat locomotor activity</ArticleTitle>
                  <JournalTitle>Behav Brain Res</JournalTitle>
                  <VolumeID>99</VolumeID>
                  <FirstPage>201</FirstPage>
                  <LastPage>208</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10512586</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXmtVKjtQ%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0166-4328(98)00104-1</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Izenwasser S, French D, Carroll FI, Funko PM. Continuous infusion of selective dopamine uptake inhibitors or cocaine produces time-dependent changes in rat locomotor activity.<Emphasis Type="Italic">Behav Brain Res</Emphasis>. 1999;99:201–208.</BibUnstructured>
              </Citation>
              <Citation ID="CR47">
                <CitationNumber>47.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JB</Initials>
                    <FamilyName>Acri</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AC</Initials>
                    <FamilyName>Thompson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Shippenberg</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Modulation of pre- and postsynaptic dopamine D2 receptor function by the selective kappaopioid receptor agonist U 69593</ArticleTitle>
                  <JournalTitle>Synapse</JournalTitle>
                  <VolumeID>39</VolumeID>
                  <FirstPage>343</FirstPage>
                  <LastPage>350</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11169785</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXhtVGntbc%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/1098-2396(20010315)39:4&lt;343::AID-SYN1018&gt;3.0.CO;2-Q</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Acri JB, Thompson AC, Shippenberg T. Modulation of pre- and postsynaptic dopamine D2 receptor function by the selective kappaopioid receptor agonist U 69593.<Emphasis Type="Italic">Synapse</Emphasis>. 2001;39:343–350.</BibUnstructured>
              </Citation>
              <Citation ID="CR48">
                <CitationNumber>48.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>CA</Initials>
                    <FamilyName>Heidbreder</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Schenk</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Partridge</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TS</Initials>
                    <FamilyName>Shippenberg</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Increased responsiveness of mesolimbic and mesostriatal dopamine neurons to cocaine following repeated administration of a selective kappa-opioid receptor agonist</ArticleTitle>
                  <JournalTitle>Synapse</JournalTitle>
                  <VolumeID>30</VolumeID>
                  <FirstPage>255</FirstPage>
                  <LastPage>262</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9776129</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXmsVGntL0%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/(SICI)1098-2396(199811)30:3&lt;255::AID-SYN3&gt;3.0.CO;2-A</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Heidbreder CA, Schenk S, Partridge B, Shippenberg TS. Increased responsiveness of mesolimbic and mesostriatal dopamine neurons to cocaine following repeated administration of a selective kappa-opioid receptor agonist.<Emphasis Type="Italic">Synapse</Emphasis>. 1998;30:255–262.</BibUnstructured>
              </Citation>
              <Citation ID="CR49">
                <CitationNumber>49.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SL</Initials>
                    <FamilyName>Collins</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RM</Initials>
                    <FamilyName>Gerdes</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>D’Addario</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Izenwasser</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Kappa opioid agonists alter dopamine markers and cocaine-stimulated locomotor activity</ArticleTitle>
                  <JournalTitle>Behav Pharmacol</JournalTitle>
                  <VolumeID>12</VolumeID>
                  <FirstPage>237</FirstPage>
                  <LastPage>245</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11548109</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXmvV2ksLk%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Collins SL, Gerdes RM, D’Addario C, Izenwasser S. Kappa opioid agonists alter dopamine markers and cocaine-stimulated locomotor activity.<Emphasis Type="Italic">Behav Pharmacol</Emphasis>. 2001;12:237–245.</BibUnstructured>
              </Citation>
              <Citation ID="CR50">
                <CitationNumber>50.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SL</Initials>
                    <FamilyName>Collins</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>D’Addario</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Izenwasser</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Effects of κ-opioid receptor agonists on long-term cocaine use and dopamine neurotransmission</ArticleTitle>
                  <JournalTitle>Eur J Pharmacol</JournalTitle>
                  <VolumeID>426</VolumeID>
                  <FirstPage>25</FirstPage>
                  <LastPage>34</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11525767</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXmt1Kkurw%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0014-2999(01)01194-3</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Collins SL, D’Addario C, Izenwasser S. Effects of κ-opioid receptor agonists on long-term cocaine use and dopamine neurotransmission.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 2001;426:25–34.</BibUnstructured>
              </Citation>
              <Citation ID="CR51">
                <CitationNumber>51.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Zhang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ER</Initials>
                    <FamilyName>Butelman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SD</Initials>
                    <FamilyName>Schlussman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Ho</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MJ</Initials>
                    <FamilyName>Kreek</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Effect of the kappa opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice</ArticleTitle>
                  <JournalTitle>Psychopharmacology (Berl)</JournalTitle>
                  <VolumeID>173</VolumeID>
                  <FirstPage>146</FirstPage>
                  <LastPage>152</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXivFSrtL4%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s00213-003-1716-3</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ. Effect of the kappa opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 2004;173:146–152.</BibUnstructured>
              </Citation>
              <Citation ID="CR52">
                <CitationNumber>52.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Zhang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ER</Initials>
                    <FamilyName>Butelman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SD</Initials>
                    <FamilyName>Schlussman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Ho</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MJ</Initials>
                    <FamilyName>Kreek</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Effect of the endogenous κ opioid agonist dynorphim A(1–17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice</ArticleTitle>
                  <JournalTitle>Psychopharmacology (Berl)</JournalTitle>
                  <VolumeID>172</VolumeID>
                  <FirstPage>422</FirstPage>
                  <LastPage>429</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXis1eks7s%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s00213-003-1688-3</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ. Effect of the endogenous κ opioid agonist dynorphim A(1–17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 2004;172:422–429.</BibUnstructured>
              </Citation>
              <Citation ID="CR53">
                <CitationNumber>53.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Schenk</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Partridge</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TS</Initials>
                    <FamilyName>Shippenberg</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Reinstatement of extinguished drug-taking behavior in rats: effect of the kappa-opioid receptor agonist, U69593</ArticleTitle>
                  <JournalTitle>Psychopharmacology (Berl)</JournalTitle>
                  <VolumeID>151</VolumeID>
                  <FirstPage>85</FirstPage>
                  <LastPage>90</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXmtV2mtbY%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s002130000476</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Schenk S, Partridge B, Shippenberg TS. Reinstatement of extinguished drug-taking behavior in rats: effect of the kappa-opioid receptor agonist, U69593.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 2000;151:85–90.</BibUnstructured>
              </Citation>
              <Citation ID="CR54">
                <CitationNumber>54.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JL</Initials>
                    <FamilyName>Neumeyer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>XH</Initials>
                    <FamilyName>Gu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LA</Initials>
                    <FamilyName>Vliet</FamilyName>
                    <Particle>van</Particle>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan</ArticleTitle>
                  <JournalTitle>Bioorg Med Chem Lett</JournalTitle>
                  <VolumeID>11</VolumeID>
                  <FirstPage>2735</FirstPage>
                  <LastPage>2740</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11591513</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXnsVKmuro%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0960-894X(01)00543-1</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Neumeyer JL, Gu XH, van Vliet LA, et al. Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan.<Emphasis Type="Italic">Bioorg Med Chem Lett</Emphasis>. 2001;11:2735–2740.</BibUnstructured>
              </Citation>
              <Citation ID="CR55">
                <CitationNumber>55.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>RS</Initials>
                    <FamilyName>Zukin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Eghbali</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Olive</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EM</Initials>
                    <FamilyName>Unterwald</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Tempel</FamilyName>
                  </BibAuthorName>
                  <Year>1988</Year>
                  <ArticleTitle Language="En">Characterization and visualization of rat and guinea pig brain kappa opioid receptors: evidence for kappa, 1 and kappa 2 opioid receptors</ArticleTitle>
                  <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                  <VolumeID>85</VolumeID>
                  <FirstPage>4061</FirstPage>
                  <LastPage>4065</LastPage>
                  <Occurrence Type="PID">
                    <Handle>2836869</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL1cXks1Kks7k%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1073/pnas.85.11.4061</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Zukin RS, Eghbali M, Olive D, Unterwald EM, Tempel A. Characterization and visualization of rat and guinea pig brain kappa opioid receptors: evidence for kappa, 1 and kappa 2 opioid receptors.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1988;85:4061–4065.</BibUnstructured>
              </Citation>
              <Citation ID="CR56">
                <CitationNumber>56.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>ER</Initials>
                    <FamilyName>Butelman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MC</Initials>
                    <FamilyName>Ko</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Sobczyk-Kojiro</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">kappa-Opioid receptor binding populations in rhesus monkey brain: relationship to an assay of thermal antinociception</ArticleTitle>
                  <JournalTitle>J Pharmacol Exp Ther</JournalTitle>
                  <VolumeID>285</VolumeID>
                  <FirstPage>595</FirstPage>
                  <LastPage>601</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9580603</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXjtF2gurg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Butelman ER, Ko MC, Sobczyk-Kojiro K, et al. kappa-Opioid receptor binding populations in rhesus monkey brain: relationship to an assay of thermal antinociception.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 1998;285:595–601.</BibUnstructured>
              </Citation>
              <Citation ID="CR57">
                <CitationNumber>57.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>RM</Initials>
                    <FamilyName>Caudle</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AA</Initials>
                    <FamilyName>Finegold</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AJ</Initials>
                    <FamilyName>Mannes</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Spinal kappa<Subscript>1</Subscript> and kappa<Subscript>2</Subscript> opioid binding sites in rats, guinea pigs, monkeys and humans</ArticleTitle>
                  <JournalTitle>Neuroreport</JournalTitle>
                  <VolumeID>9</VolumeID>
                  <FirstPage>2523</FirstPage>
                  <LastPage>2525</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9721926</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXlvVCltrk%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1097/00001756-199808030-00018</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Caudle RM, Finegold AA, Mannes AJ, et al. Spinal kappa<Subscript>1</Subscript> and kappa<Subscript>2</Subscript> opioid binding sites in rats, guinea pigs, monkeys and humans.<Emphasis Type="Italic">Neuroreport</Emphasis>. 1998;9:2523–2525.</BibUnstructured>
              </Citation>
              <Citation ID="CR58">
                <CitationNumber>58.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Wollemann</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Benyhe</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Simon</FamilyName>
                  </BibAuthorName>
                  <Year>1993</Year>
                  <ArticleTitle Language="En">The kappa-opioid receptor: evidence for the different subtypes</ArticleTitle>
                  <JournalTitle>Life Sci</JournalTitle>
                  <VolumeID>52</VolumeID>
                  <FirstPage>599</FirstPage>
                  <LastPage>611</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8381501</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK3sXhtl2jtbk%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0024-3205(93)90451-8</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Wollemann M, Benyhe S, Simon J. The kappa-opioid receptor: evidence for the different subtypes.<Emphasis Type="Italic">Life Sci</Emphasis>. 1993;52:599–611.</BibUnstructured>
              </Citation>
              <Citation ID="CR59">
                <CitationNumber>59.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>Q</Initials>
                    <FamilyName>Ni</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Xu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JS</Initials>
                    <FamilyName>Partilla</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1993</Year>
                  <ArticleTitle Language="En">Selective labeling of {ieE597-1} opioid receptors in rat brain by [<Superscript>125</Superscript>I]IOXY: interaction of opioid peptides and other drugs with multiple {ieE597-2} binding sites</ArticleTitle>
                  <JournalTitle>Peptides</JournalTitle>
                  <VolumeID>14</VolumeID>
                  <FirstPage>1279</FirstPage>
                  <LastPage>1293</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8134311</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2cXht1Gjt7g%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0196-9781(93)90188-M</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Ni Q, Xu H, Partilla JS, et al. Selective labeling of {ieE597-1} opioid receptors in rat brain by [<Superscript>125</Superscript>I]IOXY: interaction of opioid peptides and other drugs with multiple {ieE597-2} binding sites.<Emphasis Type="Italic">Peptides</Emphasis>. 1993;14:1279–1293.</BibUnstructured>
              </Citation>
              <Citation ID="CR60">
                <CitationNumber>60.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>RB</Initials>
                    <FamilyName>Rothman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>V</Initials>
                    <FamilyName>Bykov</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>BG</Initials>
                    <FamilyName>Xue</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1992</Year>
                  <ArticleTitle Language="En">Interaction of opioid peptides and other drugs with multiple kappa receptors in rat and human brain. Evidence for species differences</ArticleTitle>
                  <JournalTitle>Peptides</JournalTitle>
                  <VolumeID>13</VolumeID>
                  <FirstPage>977</FirstPage>
                  <LastPage>987</LastPage>
                  <Occurrence Type="PID">
                    <Handle>1336192</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK3sXhtFKh</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0196-9781(92)90059-C</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Rothman RB, Bykov V, Xue BG, et al. Interaction of opioid peptides and other drugs with multiple kappa receptors in rat and human brain. Evidence for species differences.<Emphasis Type="Italic">Peptides</Emphasis>. 1992;13:977–987.</BibUnstructured>
              </Citation>
              <Citation ID="CR61">
                <CitationNumber>61.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>RA</Initials>
                    <FamilyName>Lahti</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MM</Initials>
                    <FamilyName>Mickelson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JM</Initials>
                    <FamilyName>McCall</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PF</Initials>
                    <FamilyName>Voigtlander</FamilyName>
                    <Particle>Von</Particle>
                  </BibAuthorName>
                  <Year>1985</Year>
                  <ArticleTitle Language="En">[<Superscript>3</Superscript>H]U-69593 a highly selective ligand for the opioid kappa receptor</ArticleTitle>
                  <JournalTitle>Eur J Pharmacol</JournalTitle>
                  <VolumeID>109</VolumeID>
                  <FirstPage>281</FirstPage>
                  <LastPage>284</LastPage>
                  <Occurrence Type="PID">
                    <Handle>2986999</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL2MXktVSntL8%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0014-2999(85)90431-5</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Lahti RA, Mickelson MM, McCall JM, Von Voigtlander PF. [<Superscript>3</Superscript>H]U-69593 a highly selective ligand for the opioid kappa receptor.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 1985;109:281–284.</BibUnstructured>
              </Citation>
              <Citation ID="CR62">
                <CitationNumber>62.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Romer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Buscher</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RC</Initials>
                    <FamilyName>Hill</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1980</Year>
                  <ArticleTitle Language="En">Bremazocine: a potent, longacting opiate kappa-agonist</ArticleTitle>
                  <JournalTitle>Life Sci</JournalTitle>
                  <VolumeID>27</VolumeID>
                  <FirstPage>971</FirstPage>
                  <LastPage>978</LastPage>
                  <Occurrence Type="PID">
                    <Handle>6253759</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaL3M%2FltFCrtQ%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0024-3205(80)90107-1</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Romer D, Buscher H, Hill RC, et al. Bremazocine: a potent, longacting opiate kappa-agonist.<Emphasis Type="Italic">Life Sci</Emphasis>. 1980;27:971–978.</BibUnstructured>
              </Citation>
              <Citation ID="CR63">
                <CitationNumber>63.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>PS</Initials>
                    <FamilyName>Portoghese</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AW</Initials>
                    <FamilyName>Lipkowski</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AE</Initials>
                    <FamilyName>Takemori</FamilyName>
                  </BibAuthorName>
                  <Year>1987</Year>
                  <ArticleTitle Language="En">Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists</ArticleTitle>
                  <JournalTitle>Life Sci</JournalTitle>
                  <VolumeID>40</VolumeID>
                  <FirstPage>1287</FirstPage>
                  <LastPage>1292</LastPage>
                  <Occurrence Type="PID">
                    <Handle>2882399</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL2sXksFWku7s%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0024-3205(87)90585-6</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Portoghese PS, Lipkowski AW, Takemori AE. Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists.<Emphasis Type="Italic">Life Sci</Emphasis>. 1987;40:1287–1292.</BibUnstructured>
              </Citation>
              <Citation ID="CR64">
                <CitationNumber>64.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>PS</Initials>
                    <FamilyName>Portoghese</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Garzon-Aburbeh</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Nagase</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CE</Initials>
                    <FamilyName>Lin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AE</Initials>
                    <FamilyName>Takemori</FamilyName>
                  </BibAuthorName>
                  <Year>1991</Year>
                  <ArticleTitle Language="En">Role of the spacer in conferring kappa opioid receptor selectivity to bivalent ligands related to norbinaltorphimine</ArticleTitle>
                  <JournalTitle>J Med Chem</JournalTitle>
                  <VolumeID>34</VolumeID>
                  <FirstPage>1292</FirstPage>
                  <LastPage>1296</LastPage>
                  <Occurrence Type="PID">
                    <Handle>1849995</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK3MXhvVGrsrs%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1021/jm00108a008</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Portoghese PS, Garzon-Aburbeh A, Nagase H, Lin CE, Takemori AE. Role of the spacer in conferring kappa opioid receptor selectivity to bivalent ligands related to norbinaltorphimine.<Emphasis Type="Italic">J Med Chem</Emphasis>. 1991;34:1292–1296.</BibUnstructured>
              </Citation>
              <Citation ID="CR65">
                <CitationNumber>65.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JA</Initials>
                    <FamilyName>Clark</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Liu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Price</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1989</Year>
                  <ArticleTitle Language="En">Kappa opiate receptor multiplicity: evidence for two U50,488-sensitive kappa1 subtypes and a novel kappa3, subtype</ArticleTitle>
                  <JournalTitle>J Pharmacol Exp Ther</JournalTitle>
                  <VolumeID>251</VolumeID>
                  <FirstPage>461</FirstPage>
                  <LastPage>468</LastPage>
                  <Occurrence Type="PID">
                    <Handle>2553920</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK3cXjtVymtw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Clark JA, Liu L, Price M, et al. Kappa opiate receptor multiplicity: evidence for two U50,488-sensitive kappa1 subtypes and a novel kappa3, subtype.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 1989;251:461–468.</BibUnstructured>
              </Citation>
              <Citation ID="CR66">
                <CitationNumber>66.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Raynor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Kong</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1994</Year>
                  <ArticleTitle Language="En">Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors</ArticleTitle>
                  <JournalTitle>Mol Pharmacol</JournalTitle>
                  <VolumeID>45</VolumeID>
                  <FirstPage>330</FirstPage>
                  <LastPage>334</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8114680</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2cXhvVenurk%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Raynor K, Kong H, Chen Y, et al. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors.<Emphasis Type="Italic">Mol Pharmacol</Emphasis>. 1994;45:330–334.</BibUnstructured>
              </Citation>
              <Citation ID="CR67">
                <CitationNumber>67.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>DE</Initials>
                    <FamilyName>Rusovici</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SS</Initials>
                    <FamilyName>Negus</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>NK</Initials>
                    <FamilyName>Mello</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JM</Initials>
                    <FamilyName>Bidlack</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Kappa-opioid receptors are differentially labeled by arylacetamides and benzomorphans</ArticleTitle>
                  <JournalTitle>Eur J Pharmacol</JournalTitle>
                  <VolumeID>485</VolumeID>
                  <FirstPage>119</FirstPage>
                  <LastPage>125</LastPage>
                  <Occurrence Type="PID">
                    <Handle>14757131</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXnvVyisA%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.ejphar.2003.11.078</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Rusovici DE, Negus SS, Mello NK, Bidlack JM. Kappa-opioid receptors are differentially labeled by arylacetamides and benzomorphans.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 2004;485:119–125.</BibUnstructured>
              </Citation>
              <Citation ID="CR68">
                <CitationNumber>68.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Goldstein</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Tachibana</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LI</Initials>
                    <FamilyName>Lowney</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Hunkapiller</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Hood</FamilyName>
                  </BibAuthorName>
                  <Year>1979</Year>
                  <ArticleTitle Language="En">Dynorphin-(1–13), an extraordinarily potent opioid peptide</ArticleTitle>
                  <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                  <VolumeID>76</VolumeID>
                  <FirstPage>6666</FirstPage>
                  <LastPage>6670</LastPage>
                  <Occurrence Type="PID">
                    <Handle>230519</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL3cXht1ait7w%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1073/pnas.76.12.6666</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Goldstein A, Tachibana S, Lowney LI, Hunkapiller M, Hood L. Dynorphin-(1–13), an extraordinarily potent opioid peptide.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1979;76:6666–6670.</BibUnstructured>
              </Citation>
              <Citation ID="CR69">
                <CitationNumber>69.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Chavkin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>IF</Initials>
                    <FamilyName>James</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Goldstein</FamilyName>
                  </BibAuthorName>
                  <Year>1982</Year>
                  <ArticleTitle Language="En">Dynorphin is a specific endogenous ligand of the kappa opioid receptor</ArticleTitle>
                  <JournalTitle>Science</JournalTitle>
                  <VolumeID>215</VolumeID>
                  <FirstPage>413</FirstPage>
                  <LastPage>415</LastPage>
                  <Occurrence Type="PID">
                    <Handle>6120570</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL38XhtFKntbc%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1126/science.6120570</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Chavkin C, James IF, Goldstein A. Dynorphin is a specific endogenous ligand of the kappa opioid receptor.<Emphasis Type="Italic">Science</Emphasis>: 1982;215:413–415.</BibUnstructured>
              </Citation>
              <Citation ID="CR70">
                <CitationNumber>70.</CitationNumber>
                <BibBook>
                  <BibAuthorName>
                    <Initials>AF</Initials>
                    <FamilyName>Casy</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RT</Initials>
                    <FamilyName>Parfitt</FamilyName>
                  </BibAuthorName>
                  <Year>1986</Year>
                  <BookTitle>Opioid Analgesics: Chemistry and Receptors</BookTitle>
                  <PublisherName>Plenum Press</PublisherName>
                  <PublisherLocation>New York</PublisherLocation>
                </BibBook>
                <BibUnstructured>Casy AF, Parfitt RT.<Emphasis Type="Italic">Opioid Analgesics: Chemistry and Receptors</Emphasis>. New York: Plenum Press; 1986.</BibUnstructured>
              </Citation>
              <Citation ID="CR71">
                <CitationNumber>71.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Eguchi</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Recent advances in selective opioid receptor agonists and antagonists</ArticleTitle>
                  <JournalTitle>Med Res Rev</JournalTitle>
                  <VolumeID>24</VolumeID>
                  <FirstPage>182</FirstPage>
                  <LastPage>212</LastPage>
                  <Occurrence Type="PID">
                    <Handle>14705168</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXitlelsrw%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/med.10059</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Eguchi M. Recent advances in selective opioid receptor agonists and antagonists.<Emphasis Type="Italic">Med Res Rev</Emphasis>. 2004;24:182–212.</BibUnstructured>
              </Citation>
              <Citation ID="CR72">
                <CitationNumber>72.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Archer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SD</Initials>
                    <FamilyName>Glick</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JM</Initials>
                    <FamilyName>Bidlack</FamilyName>
                  </BibAuthorName>
                  <Year>1996</Year>
                  <ArticleTitle Language="En">Cyclazocine revisited</ArticleTitle>
                  <JournalTitle>Neurochem Res</JournalTitle>
                  <VolumeID>21</VolumeID>
                  <FirstPage>1369</FirstPage>
                  <LastPage>1373</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8947927</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK28Xnt1Okurg%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/BF02532378</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Archer S, Glick SD, Bidlack JM. Cyclazocine revisited.<Emphasis Type="Italic">Neurochem Res</Emphasis>. 1996;21:1369–1373.</BibUnstructured>
              </Citation>
              <Citation ID="CR73">
                <CitationNumber>73.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SD</Initials>
                    <FamilyName>Glick</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KE</Initials>
                    <FamilyName>Visker</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>IM</Initials>
                    <FamilyName>Maisonneuve</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Effects of cyclazocine on cocaine self-administration in rats</ArticleTitle>
                  <JournalTitle>Eur J Pharmacol</JournalTitle>
                  <VolumeID>357</VolumeID>
                  <FirstPage>9</FirstPage>
                  <LastPage>14</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9788768</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXlsl2nt74%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0014-2999(98)00548-2</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Glick SD, Visker KE, Maisonneuve IM. Effects of cyclazocine on cocaine self-administration in rats.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 1998;357:9–14.</BibUnstructured>
              </Citation>
              <Citation ID="CR74">
                <CitationNumber>74.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>IM</Initials>
                    <FamilyName>Maisonneuve</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SD</Initials>
                    <FamilyName>Glick</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">(+/-)Cyclazocine blocks the dopamine response to nicotine</ArticleTitle>
                  <JournalTitle>Neuroreport</JournalTitle>
                  <VolumeID>10</VolumeID>
                  <FirstPage>693</FirstPage>
                  <LastPage>696</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10208532</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXivVCltbg%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1097/00001756-199903170-00006</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Maisonneuve IM, Glick SD. (+/-)Cyclazocine blocks the dopamine response to nicotine.<Emphasis Type="Italic">Neuroreport</Emphasis>. 1999;10:693–696.</BibUnstructured>
              </Citation>
              <Citation ID="CR75">
                <CitationNumber>75.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>KL</Initials>
                    <FamilyName>Preston</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Umbricht</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JR</Initials>
                    <FamilyName>Schroeder</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Cyclazocine: comparison to hydromorphone and interaction with cocaine</ArticleTitle>
                  <JournalTitle>Behav Pharmacol</JournalTitle>
                  <VolumeID>15</VolumeID>
                  <FirstPage>91</FirstPage>
                  <LastPage>102</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15096909</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXkvFajtLc%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1097/00008877-200403000-00001</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Preston KL, Umbricht A, Schroeder JR, et al. Cyclazocine: comparison to hydromorphone and interaction with cocaine.<Emphasis Type="Italic">Behav Pharmacol</Emphasis>. 2004;15:91–102.</BibUnstructured>
              </Citation>
              <Citation ID="CR76">
                <CitationNumber>76.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>KP</Initials>
                    <FamilyName>Cosgrove</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ME</Initials>
                    <FamilyName>Carroll</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Effects of bremazocine on self-administration of smoked cocaine base and orally delivered ethanol, phencyclidine, saccharin, and food in rhesus monkeys: a behavioral economic analysis</ArticleTitle>
                  <JournalTitle>J Pharmacol Exp Ther</JournalTitle>
                  <VolumeID>301</VolumeID>
                  <FirstPage>993</FirstPage>
                  <LastPage>1002</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12023530</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XktlGjsLg%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1124/jpet.301.3.993</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Cosgrove KP, Carroll ME. Effects of bremazocine on self-administration of smoked cocaine base and orally delivered ethanol, phencyclidine, saccharin, and food in rhesus monkeys: a behavioral economic analysis.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2002;301:993–1002.</BibUnstructured>
              </Citation>
              <Citation ID="CR77">
                <CitationNumber>77.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Nestby</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AN</Initials>
                    <FamilyName>Schoffelmeer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JR</Initials>
                    <FamilyName>Homberg</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Bremazocine reduces unrestricted free-choice ethanol self-administration in rats without affecting sucrose preference</ArticleTitle>
                  <JournalTitle>Psychopharmacology (Berl)</JournalTitle>
                  <VolumeID>142</VolumeID>
                  <FirstPage>309</FirstPage>
                  <LastPage>317</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXisVChsr4%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s002130050894</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Nestby P, Schoffelmeer AN, Homberg JR, et al. Bremazocine reduces unrestricted free-choice ethanol self-administration in rats without affecting sucrose preference.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 1999;142:309–317.</BibUnstructured>
              </Citation>
              <Citation ID="CR78">
                <CitationNumber>78.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>MP</Initials>
                    <FamilyName>Wentland</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Lou</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Ye</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">8-Carboxamidocyclazocine analogues: redefining the structure-activity relationships of 2, 6-methano-3-benzazocines</ArticleTitle>
                  <JournalTitle>Bioorg Med Chem Lett</JournalTitle>
                  <VolumeID>11</VolumeID>
                  <FirstPage>623</FirstPage>
                  <LastPage>626</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11266156</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXhslOnsb8%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0960-894X(01)00014-2</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Wentland MP, Lou R, Ye Y, et al. 8-Carboxamidocyclazocine analogues: redefining the structure-activity relationships of 2, 6-methano-3-benzazocines.<Emphasis Type="Italic">Bioorg Med Chem Lett</Emphasis>. 2001;11:623–626.</BibUnstructured>
              </Citation>
              <Citation ID="CR79">
                <CitationNumber>79.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JM</Initials>
                    <FamilyName>Bidlack</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DJ</Initials>
                    <FamilyName>Cohen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JP</Initials>
                    <FamilyName>McLaughlin</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">8-Carboxamidocyclazocine: a long-acting, novel benzomorphan</ArticleTitle>
                  <JournalTitle>J Pharmacol Exp Ther</JournalTitle>
                  <VolumeID>302</VolumeID>
                  <FirstPage>374</FirstPage>
                  <LastPage>380</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12065740</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38Xlt1SnsLk%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1124/jpet.302.1.374</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bidlack JM, Cohen DJ, McLaughlin JP, et al. 8-Carboxamidocyclazocine: a long-acting, novel benzomorphan.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2002;302:374–380.</BibUnstructured>
              </Citation>
              <Citation ID="CR80">
                <CitationNumber>80.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>GW</Initials>
                    <FamilyName>Stevenson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MP</Initials>
                    <FamilyName>Wentland</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JM</Initials>
                    <FamilyName>Bidlack</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>NK</Initials>
                    <FamilyName>Mello</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SS</Initials>
                    <FamilyName>Negus</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Effects of the mixed-action kappa/mu opioid agonist 8-carboxamidocyclazocine on cocaine- and food-maintained responding in rhesus monkeys</ArticleTitle>
                  <JournalTitle>Eur J Pharmacol</JournalTitle>
                  <VolumeID>506</VolumeID>
                  <FirstPage>133</FirstPage>
                  <LastPage>141</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15588733</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXhtVGgu7bE</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.ejphar.2004.10.051</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Stevenson GW, Wentland MP, Bidlack JM, Mello NK, Negus SS. Effects of the mixed-action kappa/mu opioid agonist 8-carboxamidocyclazocine on cocaine- and food-maintained responding in rhesus monkeys.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 2004;506:133–141.</BibUnstructured>
              </Citation>
              <Citation ID="CR81">
                <CitationNumber>81.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>CA</Initials>
                    <FamilyName>Bowen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SS</Initials>
                    <FamilyName>Negus</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Zong</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Effects of mixed-action kappa/mu opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys</ArticleTitle>
                  <JournalTitle>Neuropsychopharmacology</JournalTitle>
                  <VolumeID>28</VolumeID>
                  <FirstPage>1125</FirstPage>
                  <LastPage>1139</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12637953</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXjvF2ltLo%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bowen CA, Negus SS, Zong R, et al. Effects of mixed-action kappa/mu opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys.<Emphasis Type="Italic">Neuropsychopharmacology</Emphasis>. 2003;28:1125–1139.</BibUnstructured>
              </Citation>
              <Citation ID="CR82">
                <CitationNumber>82.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Szmuszkovicz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PF</Initials>
                    <FamilyName>Voigtlander</FamilyName>
                    <Particle>von</Particle>
                  </BibAuthorName>
                  <Year>1982</Year>
                  <ArticleTitle Language="En">Benzeneacetamide amines: structurally novel non-mμ opioids</ArticleTitle>
                  <JournalTitle>J Med Chem</JournalTitle>
                  <VolumeID>25</VolumeID>
                  <FirstPage>1125</FirstPage>
                  <LastPage>1126</LastPage>
                  <Occurrence Type="PID">
                    <Handle>6128415</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL38Xlt1Sis7Y%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1021/jm00352a005</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Szmuszkovicz J, von Voigtlander PF. Benzeneacetamide amines: structurally novel non-mμ opioids.<Emphasis Type="Italic">J Med Chem</Emphasis>. 1982;25:1125–1126.</BibUnstructured>
              </Citation>
              <Citation ID="CR83">
                <CitationNumber>83.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Szmuszkovicz</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">U-50,488 and the kappa receptor: a personalized account covering the period 1973 to 1990</ArticleTitle>
                  <JournalTitle>Prog Drug Res</JournalTitle>
                  <VolumeID>52</VolumeID>
                  <FirstPage>167</FirstPage>
                  <LastPage>195</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10396128</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXksVCmtbg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Szmuszkovicz J. U-50,488 and the kappa receptor: a personalized account covering the period 1973 to 1990.<Emphasis Type="Italic">Prog Drug Res</Emphasis>. 1999;52:167–195.</BibUnstructured>
              </Citation>
              <Citation ID="CR84">
                <CitationNumber>84.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Szmuszkovicz</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">U-50,488 and the kappa receptor. Part II: 1991–1998</ArticleTitle>
                  <JournalTitle>Prog Drug Res</JournalTitle>
                  <VolumeID>53</VolumeID>
                  <FirstPage>1</FirstPage>
                  <LastPage>51</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10616295</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXnvFKgs7c%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Szmuszkovicz J. U-50,488 and the kappa receptor. Part II: 1991–1998.<Emphasis Type="Italic">Prog Drug Res</Emphasis>. 1999;53:1–51.</BibUnstructured>
              </Citation>
              <Citation ID="CR85">
                <CitationNumber>85.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>IM</Initials>
                    <FamilyName>Maisonneuve</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Archer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SD</Initials>
                    <FamilyName>Glick</FamilyName>
                  </BibAuthorName>
                  <Year>1994</Year>
                  <ArticleTitle Language="En">U50,488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats</ArticleTitle>
                  <JournalTitle>Neurosci Lett</JournalTitle>
                  <VolumeID>181</VolumeID>
                  <FirstPage>57</FirstPage>
                  <LastPage>60</LastPage>
                  <Occurrence Type="PID">
                    <Handle>7898771</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2MXhslOntr4%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0304-3940(94)90559-2</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Maisonneuve IM, Archer S, Glick SD. U50,488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats.<Emphasis Type="Italic">Neurosci Lett</Emphasis>. 1994;181:57–60.</BibUnstructured>
              </Citation>
              <Citation ID="CR86">
                <CitationNumber>86.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Broadbent</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TM</Initials>
                    <FamilyName>Gaspard</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SI</Initials>
                    <FamilyName>Dworkin</FamilyName>
                  </BibAuthorName>
                  <Year>1995</Year>
                  <ArticleTitle Language="En">Assessment of the discriminative stimulus effects of cocaine in the rat: lack of interaction with opioids</ArticleTitle>
                  <JournalTitle>Pharmacol Biochem Behav</JournalTitle>
                  <VolumeID>51</VolumeID>
                  <FirstPage>379</FirstPage>
                  <LastPage>385</LastPage>
                  <Occurrence Type="PID">
                    <Handle>7667357</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2MXlvFylsb4%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0091-3057(94)00408-B</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Broadbent J, Gaspard TM, Dworkin SI. Assessment of the discriminative stimulus effects of cocaine in the rat: lack of interaction with opioids.<Emphasis Type="Italic">Pharmacol Biochem Behav</Emphasis>. 1995;51:379–385.</BibUnstructured>
              </Citation>
              <Citation ID="CR87">
                <CitationNumber>87.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SD</Initials>
                    <FamilyName>Glick</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>IM</Initials>
                    <FamilyName>Maisonneuve</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Raucci</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Archer</FamilyName>
                  </BibAuthorName>
                  <Year>1995</Year>
                  <ArticleTitle Language="En">Kappa opioid inhibition of morphine and cocaine self-administration in rats</ArticleTitle>
                  <JournalTitle>Brain Res</JournalTitle>
                  <VolumeID>681</VolumeID>
                  <FirstPage>147</FirstPage>
                  <LastPage>152</LastPage>
                  <Occurrence Type="PID">
                    <Handle>7552272</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2MXmtVyntb0%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0006-8993(95)00306-B</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Glick SD, Maisonneuve IM, Raucci J, Archer S. Kappa opioid inhibition of morphine and cocaine self-administration in rats.<Emphasis Type="Italic">Brain Res</Emphasis>. 1995;681:147–152.</BibUnstructured>
              </Citation>
              <Citation ID="CR88">
                <CitationNumber>88.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AV</Initials>
                    <FamilyName>Kuzmin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Semenova</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MA</Initials>
                    <FamilyName>Gerrits</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EE</Initials>
                    <FamilyName>Zvartan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JM</Initials>
                    <FamilyName>Ree</FamilyName>
                    <Particle>Van</Particle>
                  </BibAuthorName>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">Kappa-opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naive rats and mice</ArticleTitle>
                  <JournalTitle>Eur J Pharmacol</JournalTitle>
                  <VolumeID>321</VolumeID>
                  <FirstPage>265</FirstPage>
                  <LastPage>271</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9085036</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2sXhvFKjs74%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0014-2999(96)00961-2</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kuzmin AV, Semenova S, Gerrits MA, Zvartan EE, Van Ree JM. Kappa-opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naive rats and mice.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 1997;321:265–271.</BibUnstructured>
              </Citation>
              <Citation ID="CR89">
                <CitationNumber>89.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>KM</Initials>
                    <FamilyName>Kantak</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Riberdy</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RD</Initials>
                    <FamilyName>Spealman</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Cocaine-opioid interactions in groups of rats trained to discriminate different doses of cocaine</ArticleTitle>
                  <JournalTitle>Psychopharmacology (Berl)</JournalTitle>
                  <VolumeID>147</VolumeID>
                  <FirstPage>257</FirstPage>
                  <LastPage>265</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXpslKkug%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s002130051165</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kantak KM, Riberdy A, Spealman RD. Cocaine-opioid interactions in groups of rats trained to discriminate different doses of cocaine.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 1999;147:257–265.</BibUnstructured>
              </Citation>
              <Citation ID="CR90">
                <CitationNumber>90.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SS</Initials>
                    <FamilyName>Negus</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>NK</Initials>
                    <FamilyName>Mello</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PS</Initials>
                    <FamilyName>Portoghese</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C-E</Initials>
                    <FamilyName>Lin</FamilyName>
                  </BibAuthorName>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">Effects of<Emphasis Type="Italic">kappa</Emphasis> opioids on cocaine self-administration by rhesus monkeys</ArticleTitle>
                  <JournalTitle>J Pharmacol Exp Ther</JournalTitle>
                  <VolumeID>282</VolumeID>
                  <FirstPage>44</FirstPage>
                  <LastPage>55</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9223538</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2sXksFOhtbo%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Negus SS, Mello NK, Portoghese PS, Lin C-E. Effects of<Emphasis Type="Italic">kappa</Emphasis> opioids on cocaine self-administration by rhesus monkeys.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 1997;282:44–55.</BibUnstructured>
              </Citation>
              <Citation ID="CR91">
                <CitationNumber>91.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SS</Initials>
                    <FamilyName>Negus</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>NK</Initials>
                    <FamilyName>Mello</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Effects of kappa opioid agonists on the discriminative stimulus effects of cocaine in rhesus monkeys</ArticleTitle>
                  <JournalTitle>Exp Clin Psychopharmacol</JournalTitle>
                  <VolumeID>7</VolumeID>
                  <FirstPage>307</FirstPage>
                  <LastPage>317</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10609965</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXivFenuw%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1037/1064-1297.7.4.307</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Negus SS, Mello NK. Effects of kappa opioid agonists on the discriminative stimulus effects of cocaine in rhesus monkeys.<Emphasis Type="Italic">Exp Clin Psychopharmacol</Emphasis>. 1999;7:307–317.</BibUnstructured>
              </Citation>
              <Citation ID="CR92">
                <CitationNumber>92.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SS</Initials>
                    <FamilyName>Negus</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Effects of the kappa opioid agonist U50,488 and the kappa opioid antagonist nor-binaltorphimine on choice between cocaine and food in rhesus monkeys</ArticleTitle>
                  <JournalTitle>Psychopharmacology (Berl)</JournalTitle>
                  <VolumeID>176</VolumeID>
                  <FirstPage>204</FirstPage>
                  <LastPage>213</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s00213-004-1878-7</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXoslSltb8%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Negus SS. Effects of the kappa opioid agonist U50,488 and the kappa opioid antagonist nor-binaltorphimine on choice between cocaine and food in rhesus monkeys.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 2004;176:204–213.</BibUnstructured>
              </Citation>
              <Citation ID="CR93">
                <CitationNumber>93.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Schenk</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Partridge</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TS</Initials>
                    <FamilyName>Shippenberg</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking</ArticleTitle>
                  <JournalTitle>Psychopharmacology (Berl)</JournalTitle>
                  <VolumeID>144</VolumeID>
                  <FirstPage>339</FirstPage>
                  <LastPage>346</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXkslKlu7s%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s002130051016</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Schenk S, Partridge B, Shippenberg TS. U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 1999;144:339–346.</BibUnstructured>
              </Citation>
              <Citation ID="CR94">
                <CitationNumber>94.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>LJ</Initials>
                    <FamilyName>Vanderschuren</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AN</Initials>
                    <FamilyName>Schoffelmeer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Wardeh</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TJ</Initials>
                    <FamilyName>Vries</FamilyName>
                    <Particle>De</Particle>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Dissociable effects of the kappa-opioid receptor agonists bremazocine, U69593, and U50488H on locomotor activity and long-term behavioral sensitization induced by amphetamine and cocaine</ArticleTitle>
                  <JournalTitle>Psychopharmacology (Berl)</JournalTitle>
                  <VolumeID>150</VolumeID>
                  <FirstPage>35</FirstPage>
                  <LastPage>44</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXkt1egtbk%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s002130000424</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Vanderschuren LJ, Schoffelmeer AN, Wardeh G, De Vries TJ. Dissociable effects of the kappa-opioid receptor agonists bremazocine, U69593, and U50488H on locomotor activity and long-term behavioral sensitization induced by amphetamine and cocaine.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 2000;150:35–44.</BibUnstructured>
              </Citation>
              <Citation ID="CR95">
                <CitationNumber>95.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Daly</FamilyName>
                    <Particle>El</Particle>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>V</Initials>
                    <FamilyName>Chefer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Sandill</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TS</Initials>
                    <FamilyName>Shippenberg</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Modulation of the neurotoxic effects of methamphetamine by the selective κ opioid receptor agonist U69593</ArticleTitle>
                  <JournalTitle>J Neurochem</JournalTitle>
                  <VolumeID>74</VolumeID>
                  <FirstPage>1553</FirstPage>
                  <LastPage>1562</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10737612</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1046/j.1471-4159.2000.0741553.x</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>El Daly E, Chefer V, Sandill S, Shippenberg TS. Modulation of the neurotoxic effects of methamphetamine by the selective κ opioid receptor agonist U69593.<Emphasis Type="Italic">J Neurochem</Emphasis>. 2000;74:1553–1562.</BibUnstructured>
              </Citation>
              <Citation ID="CR96">
                <CitationNumber>96.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>KR</Initials>
                    <FamilyName>Powell</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SG</Initials>
                    <FamilyName>Holtzman</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Modulation of the discriminative stimulus effects of d-amphetamine by mu and kappa opioids in squirrel monkeys</ArticleTitle>
                  <JournalTitle>Pharmacol Biochem Behav</JournalTitle>
                  <VolumeID>65</VolumeID>
                  <FirstPage>43</FirstPage>
                  <LastPage>51</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10638635</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXotlWg</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0091-3057(99)00183-5</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Powell KR, Holtzman SG. Modulation of the discriminative stimulus effects of d-amphetamine by mu and kappa opioids in squirrel monkeys.<Emphasis Type="Italic">Pharmacol Biochem Behav</Emphasis>. 2000;65:43–51.</BibUnstructured>
              </Citation>
              <Citation ID="CR97">
                <CitationNumber>97.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Sorbera</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Castaner</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Leeson</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Nalfurafine hydrochloride. Antipruritic, analgesic, kappa opioid agonist</ArticleTitle>
                  <JournalTitle>Drugs of the Future</JournalTitle>
                  <VolumeID>28</VolumeID>
                  <FirstPage>237</FirstPage>
                  <LastPage>242</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXkvVCju7w%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1358/dof.2003.028.03.723584</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Sorbera L, Castaner J, Leeson P. Nalfurafine hydrochloride. Antipruritic, analgesic, kappa opioid agonist.<Emphasis Type="Italic">Drugs of the Future</Emphasis>. 2003;28:237–242.</BibUnstructured>
              </Citation>
              <Citation ID="CR98">
                <CitationNumber>98.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Nagase</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Hayakawa</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Kawamura</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Discovery of a structurally novel opioid κ-agonist derived from 4,5-epoxymorphinan</ArticleTitle>
                  <JournalTitle>Chem Pharm Bull (Tokyo)</JournalTitle>
                  <VolumeID>46</VolumeID>
                  <FirstPage>366</FirstPage>
                  <LastPage>369</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXhtlChsb8%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Nagase H, Hayakawa J, Kawamura K, et al. Discovery of a structurally novel opioid κ-agonist derived from 4,5-epoxymorphinan.<Emphasis Type="Italic">Chem Pharm Bull (Tokyo)</Emphasis>. 1998;46:366–369.</BibUnstructured>
              </Citation>
              <Citation ID="CR99">
                <CitationNumber>99.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Tang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Inan</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Comparison of pharmacological activities of three distinet κ-ligands (Salvinorin A, TRK-820 and 3 FLB) on κ opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo</ArticleTitle>
                  <JournalTitle>J Pharmacol Exp Ther</JournalTitle>
                  <VolumeID>312</VolumeID>
                  <FirstPage>220</FirstPage>
                  <LastPage>230</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15383632</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1124/jpet.104.073668</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2MXhtVWmtLY%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Wang Y, Tang K, Inan S, et al. Comparison of pharmacological activities of three distinet κ-ligands (Salvinorin A, TRK-820 and 3 FLB) on κ opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2004;312:220–230.</BibUnstructured>
              </Citation>
              <Citation ID="CR100">
                <CitationNumber>100.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Endoh</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Tajima</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Izumimoto</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">TRK-820, a selective κ-opioid agonist, produces potent antinociception in cynomolgus monkeys</ArticleTitle>
                  <JournalTitle>Jpn J Pharmacol</JournalTitle>
                  <VolumeID>85</VolumeID>
                  <FirstPage>282</FirstPage>
                  <LastPage>290</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11325021</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXitlSlsL4%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1254/jjp.85.282</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Endoh T, Tajima A, Izumimoto N, et al. TRK-820, a selective κ-opioid agonist, produces potent antinociception in cynomolgus monkeys.<Emphasis Type="Italic">Jpn J Pharmacol</Emphasis>. 2001;85:282–290.</BibUnstructured>
              </Citation>
              <Citation ID="CR101">
                <CitationNumber>101.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Endoh</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Matsuura</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Tajima</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Potent antinociceptive effects of TRK-820, a novel κ-opioid receptor agonist</ArticleTitle>
                  <JournalTitle>Life Sci</JournalTitle>
                  <VolumeID>65</VolumeID>
                  <FirstPage>1685</FirstPage>
                  <LastPage>1694</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10573186</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXmtFalt7k%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0024-3205(99)00417-8</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Endoh T, Matsuura H, Tajima A, et al. Potent antinociceptive effects of TRK-820, a novel κ-opioid receptor agonist.<Emphasis Type="Italic">Life Sci</Emphasis>. 1999;65:1685–1694.</BibUnstructured>
              </Citation>
              <Citation ID="CR102">
                <CitationNumber>102.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Endoh</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Tajima</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Suzuki</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Characterization of the antinociceptive effects of TRK-820 in the rat</ArticleTitle>
                  <JournalTitle>Eur J Pharmacol</JournalTitle>
                  <VolumeID>387</VolumeID>
                  <FirstPage>133</FirstPage>
                  <LastPage>140</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10650153</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXmtVyhug%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0014-2999(99)00815-8</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Endoh T, Tajima A, Suzuki T, et al. Characterization of the antinociceptive effects of TRK-820 in the rat.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 2000;387:133–140.</BibUnstructured>
              </Citation>
              <Citation ID="CR103">
                <CitationNumber>103.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Suzuki</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Izumimoto</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Takezawa</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Effect of repeated administration of TRK-820, a κ-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions</ArticleTitle>
                  <JournalTitle>Brain Res</JournalTitle>
                  <VolumeID>995</VolumeID>
                  <FirstPage>167</FirstPage>
                  <LastPage>175</LastPage>
                  <Occurrence Type="PID">
                    <Handle>14672806</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXps1Gktrc%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.brainres.2003.09.057</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Suzuki T, Izumimoto N, Takezawa Y, et al. Effect of repeated administration of TRK-820, a κ-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions.<Emphasis Type="Italic">Brain Res</Emphasis>. 2004;995:167–175.</BibUnstructured>
              </Citation>
              <Citation ID="CR104">
                <CitationNumber>104.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Mori</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Nomura</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Nagase</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Narita</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Suzuki</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Effects of a newly synthesized κ-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats</ArticleTitle>
                  <JournalTitle>Psychopharmacology (Berl)</JournalTitle>
                  <VolumeID>161</VolumeID>
                  <FirstPage>17</FirstPage>
                  <LastPage>22</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XktFSmsrY%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s00213-002-1028-z</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mori T, Nomura M, Nagase H, Narita M, Suzuki T. Effects of a newly synthesized κ-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 2002;161:17–22.</BibUnstructured>
              </Citation>
              <Citation ID="CR105">
                <CitationNumber>105.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Hasebe</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Kawai</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Suzuki</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Possible pharmacotherapy of the opioid κ receptor agonist for drug dependence</ArticleTitle>
                  <JournalTitle>Ann NY Acad Sci</JournalTitle>
                  <VolumeID>1025</VolumeID>
                  <FirstPage>404</FirstPage>
                  <LastPage>413</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15542743</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2MXltVSgug%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1196/annals.1316.050</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hasebe K, Kawai K, Suzuki T, et al. Possible pharmacotherapy of the opioid κ receptor agonist for drug dependence.<Emphasis Type="Italic">Ann NY Acad Sci</Emphasis>. 2004;1025:404–413.</BibUnstructured>
              </Citation>
              <Citation ID="CR106">
                <CitationNumber>106.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Mori</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Nomura</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Yoshizawa</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Differential properties between TRK-820 and U-50,488H on the discriminative stimulus effects in rats</ArticleTitle>
                  <JournalTitle>Life Sci</JournalTitle>
                  <VolumeID>75</VolumeID>
                  <FirstPage>2473</FirstPage>
                  <LastPage>2482</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15350822</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXntlemurk%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.lfs.2004.05.017</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mori T, Nomura M, Yoshizawa K, et al. Differential properties between TRK-820 and U-50,488H on the discriminative stimulus effects in rats.<Emphasis Type="Italic">Life Sci</Emphasis>. 2004;75:2473–2482.</BibUnstructured>
              </Citation>
              <Citation ID="CR107">
                <CitationNumber>107.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>MS</Initials>
                    <FamilyName>Levi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RF</Initials>
                    <FamilyName>Borne</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">A review of chemical agents in the pharmacotherapy of addiction</ArticleTitle>
                  <JournalTitle>Curr Med Chem</JournalTitle>
                  <VolumeID>9</VolumeID>
                  <FirstPage>1807</FirstPage>
                  <LastPage>1818</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12369879</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XntlCqtb0%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Levi MS, Borne RF. A review of chemical agents in the pharmacotherapy of addiction.<Emphasis Type="Italic">Curr Med Chem</Emphasis>. 2002;9:1807–1818.</BibUnstructured>
              </Citation>
              <Citation ID="CR108">
                <CitationNumber>108.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>DC</Initials>
                    <FamilyName>Mash</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CA</Initials>
                    <FamilyName>Kovera</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Pablo</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures</ArticleTitle>
                  <JournalTitle>Ann NY Acad Sci</JournalTitle>
                  <VolumeID>914</VolumeID>
                  <FirstPage>394</FirstPage>
                  <LastPage>401</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11085338</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXosVakt70%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1749-6632.2000.tb05213.x</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mash DC, Kovera CA, Pablo J, et al. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.<Emphasis Type="Italic">Ann NY Acad Sci</Emphasis>. 2000;914:394–401.</BibUnstructured>
              </Citation>
              <Citation ID="CR109">
                <CitationNumber>109.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>DC</Initials>
                    <FamilyName>Mash</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CA</Initials>
                    <FamilyName>Kovera</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>BE</Initials>
                    <FamilyName>Buck</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Medication development of ibogaine as a pharmacotherapy for drug dependence</ArticleTitle>
                  <JournalTitle>Ann NY Acad Sci</JournalTitle>
                  <VolumeID>844</VolumeID>
                  <FirstPage>274</FirstPage>
                  <LastPage>292</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9668685</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXks12lsL0%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1749-6632.1998.tb08242.x</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mash DC, Kovera CA, Buck BE, et al. Medication development of ibogaine as a pharmacotherapy for drug dependence.<Emphasis Type="Italic">Ann NY Acad Sci</Emphasis>. 1998;844:274–292.</BibUnstructured>
              </Citation>
              <Citation ID="CR110">
                <CitationNumber>110.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>MH</Initials>
                    <FamilyName>Baumann</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JP</Initials>
                    <FamilyName>Pablo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SF</Initials>
                    <FamilyName>Ali</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RB</Initials>
                    <FamilyName>Rothman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DC</Initials>
                    <FamilyName>Mash</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine</ArticleTitle>
                  <JournalTitle>Ann NY Acad Sci</JournalTitle>
                  <VolumeID>914</VolumeID>
                  <FirstPage>354</FirstPage>
                  <LastPage>368</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11085335</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXosVakt74%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1749-6632.2000.tb05210.x</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Baumann MH, Pablo JP, Ali SF, Rothman RB, Mash DC. Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine.<Emphasis Type="Italic">Ann NY Acad Sci</Emphasis>. 2000;914:354–368.</BibUnstructured>
              </Citation>
              <Citation ID="CR111">
                <CitationNumber>111.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>MH</Initials>
                    <FamilyName>Baumann</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RB</Initials>
                    <FamilyName>Rothman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JP</Initials>
                    <FamilyName>Pablo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DC</Initials>
                    <FamilyName>Mash</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats</ArticleTitle>
                  <JournalTitle>J Pharmacol Exp Ther</JournalTitle>
                  <VolumeID>297</VolumeID>
                  <FirstPage>531</FirstPage>
                  <LastPage>539</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11303040</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXjt1Wls7c%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Baumann MH, Rothman RB, Pablo JP, Mash DC. In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2001;297:531–539.</BibUnstructured>
              </Citation>
              <Citation ID="CR112">
                <CitationNumber>112.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>PM</Initials>
                    <FamilyName>Sweetnam</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Lancaster</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Snowman</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1995</Year>
                  <ArticleTitle Language="En">Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine’s putative anti-addictive activity</ArticleTitle>
                  <JournalTitle>Psychopharmacology (Berl)</JournalTitle>
                  <VolumeID>118</VolumeID>
                  <FirstPage>369</FirstPage>
                  <LastPage>376</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2MXmtVensbw%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/BF02245936</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Sweetnam PM, Lancaster J, Snowman A, et al. Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine’s putative anti-addictive activity.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 1995;118:369–376.</BibUnstructured>
              </Citation>
              <Citation ID="CR113">
                <CitationNumber>113.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>D-Y</Initials>
                    <FamilyName>He</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>NNH</Initials>
                    <FamilyName>McGough</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Ravindranathan</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">Glial cell line-derived neúrotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption</ArticleTitle>
                  <JournalTitle>J Neurosci</JournalTitle>
                  <VolumeID>25</VolumeID>
                  <FirstPage>619</FirstPage>
                  <LastPage>628</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15659598</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2MXhtFOktL4%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1523/JNEUROSCI.3959-04.2005</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>He D-Y, McGough NNH, Ravindranathan A, et al. Glial cell line-derived neúrotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption.<Emphasis Type="Italic">J Neurosci</Emphasis>. 2005;25:619–628.</BibUnstructured>
              </Citation>
              <Citation ID="CR114">
                <CitationNumber>114.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>MB</Initials>
                    <FamilyName>Leal</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Michelin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DO</Initials>
                    <FamilyName>Souza</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Elisabetsky</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Ibogaine attenuation of morphine withdrawal in mice: role of glutamate N-methyl-aspartate receptors</ArticleTitle>
                  <JournalTitle>Prog Neuropsychopharmacol Biol Psychiatry</JournalTitle>
                  <VolumeID>27</VolumeID>
                  <FirstPage>781</FirstPage>
                  <LastPage>785</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12921910</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXmt1Kjt7s%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0278-5846(03)00109-X</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Leal MB, Michelin K, Souza DO, Elisabetsky E. Ibogaine attenuation of morphine withdrawal in mice: role of glutamate N-methyl-aspartate receptors.<Emphasis Type="Italic">Prog Neuropsychopharmacol Biol Psychiatry</Emphasis>. 2003;27:781–785.</BibUnstructured>
              </Citation>
              <Citation ID="CR115">
                <CitationNumber>115.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SD</Initials>
                    <FamilyName>Glick</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>IS</Initials>
                    <FamilyName>Maisonneuve</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Mechanisms of antiaddictive actions of ibogaine</ArticleTitle>
                  <JournalTitle>Ann N Y Acad Sci</JournalTitle>
                  <VolumeID>844</VolumeID>
                  <FirstPage>214</FirstPage>
                  <LastPage>226</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9668680</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXks12ls7Y%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1749-6632.1998.tb08237.x</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Glick SD, Maisonneuve IS. Mechanisms of antiaddictive actions of ibogaine.<Emphasis Type="Italic">Ann N Y Acad Sci</Emphasis>. 1998;844:214–226.</BibUnstructured>
              </Citation>
              <Citation ID="CR116">
                <CitationNumber>116.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SD</Initials>
                    <FamilyName>Glick</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>IM</Initials>
                    <FamilyName>Maisonneuve</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SM</Initials>
                    <FamilyName>Pearl</FamilyName>
                  </BibAuthorName>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">Evidence for roles of kappa-opioid and NMDA receptors in the mechanism of action of ibogaine</ArticleTitle>
                  <JournalTitle>Brain Res</JournalTitle>
                  <VolumeID>749</VolumeID>
                  <FirstPage>340</FirstPage>
                  <LastPage>343</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9138735</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2sXpt12guw%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0006-8993(96)01414-X</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Glick SD, Maisonneuve IM, Pearl SM. Evidence for roles of kappa-opioid and NMDA receptors in the mechanism of action of ibogaine.<Emphasis Type="Italic">Brain Res</Emphasis>. 1997;749:340–343.</BibUnstructured>
              </Citation>
              <Citation ID="CR117">
                <CitationNumber>117.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SL</Initials>
                    <FamilyName>Cappendijk</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MR</Initials>
                    <FamilyName>Dzoljic</FamilyName>
                  </BibAuthorName>
                  <Year>1993</Year>
                  <ArticleTitle Language="En">Inhibitory effects of ibogaine on cocaine self-administration in rats</ArticleTitle>
                  <JournalTitle>Eur J Pharmacol</JournalTitle>
                  <VolumeID>241</VolumeID>
                  <FirstPage>261</FirstPage>
                  <LastPage>265</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8243561</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK3sXms1agtrY%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0014-2999(93)90212-Z</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Cappendijk SL, Dzoljic MR. Inhibitory effects of ibogaine on cocaine self-administration in rats.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 1993;241:261–265.</BibUnstructured>
              </Citation>
              <Citation ID="CR118">
                <CitationNumber>118.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SD</Initials>
                    <FamilyName>Glick</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ME</Initials>
                    <FamilyName>Kuehne</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Raucci</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1994</Year>
                  <ArticleTitle Language="En">Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum</ArticleTitle>
                  <JournalTitle>Brain Res</JournalTitle>
                  <VolumeID>657</VolumeID>
                  <FirstPage>14</FirstPage>
                  <LastPage>22</LastPage>
                  <Occurrence Type="PID">
                    <Handle>7820611</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2cXmslWrurY%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0006-8993(94)90948-2</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Glick SD, Kuehne ME, Raucci J, et al. Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum.<Emphasis Type="Italic">Brain Res</Emphasis>. 1994;657:14–22.</BibUnstructured>
              </Citation>
              <Citation ID="CR119">
                <CitationNumber>119.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Sershen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Hashim</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Harsing</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Lajtha</FamilyName>
                  </BibAuthorName>
                  <Year>1992</Year>
                  <ArticleTitle Language="En">Ibogaine antagonizes cocaine-induced locomotor stimulation in mice</ArticleTitle>
                  <JournalTitle>Life Sci</JournalTitle>
                  <VolumeID>50</VolumeID>
                  <FirstPage>1079</FirstPage>
                  <LastPage>1086</LastPage>
                  <Occurrence Type="PID">
                    <Handle>1556903</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK38Xhs1KitLc%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0024-3205(92)90344-O</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Sershen H, Hashim A, Harsing L, Lajtha A. Ibogaine antagonizes cocaine-induced locomotor stimulation in mice.<Emphasis Type="Italic">Life Sci</Emphasis>. 1992;50:1079–1086.</BibUnstructured>
              </Citation>
              <Citation ID="CR120">
                <CitationNumber>120.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>IM</Initials>
                    <FamilyName>Maisonneuve</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KL</Initials>
                    <FamilyName>Rossman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RW</Initials>
                    <FamilyName>Keller</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SD</Initials>
                    <FamilyName>Glick</FamilyName>
                  </BibAuthorName>
                  <Year>1992</Year>
                  <ArticleTitle Language="En">Acute and prolonged effects of ibogaine on brain dopamine metabolism and morphine-induced locomotor activity in rats</ArticleTitle>
                  <JournalTitle>Brain Res</JournalTitle>
                  <VolumeID>575</VolumeID>
                  <FirstPage>69</FirstPage>
                  <LastPage>73</LastPage>
                  <Occurrence Type="PID">
                    <Handle>1504783</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK38XisVyhtbo%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0006-8993(92)90424-8</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Maisonneuve IM Jr, Rossman KL, Jr, Keller RW Jr, Glick SD. Acute and prolonged effects of ibogaine on brain dopamine metabolism and morphine-induced locomotor activity in rats.<Emphasis Type="Italic">Brain Res</Emphasis>. 1992;575:69–73.</BibUnstructured>
              </Citation>
              <Citation ID="CR121">
                <CitationNumber>121.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>KK</Initials>
                    <FamilyName>Szumlinski</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>IM</Initials>
                    <FamilyName>Maisonneuve</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SD</Initials>
                    <FamilyName>Glick</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Differential effects of ibogaine on behavioural and dopamine sensitization to cocaine</ArticleTitle>
                  <JournalTitle>Eur J Pharmacol</JournalTitle>
                  <VolumeID>398</VolumeID>
                  <FirstPage>259</FirstPage>
                  <LastPage>262</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10854838</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXktVSls78%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0014-2999(00)00325-3</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Szumlinski KK, Maisonneuve IM, Glick SD. Differential effects of ibogaine on behavioural and dopamine sensitization to cocaine.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 2000;398:259–262.</BibUnstructured>
              </Citation>
              <Citation ID="CR122">
                <CitationNumber>122.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>KR</Initials>
                    <FamilyName>Alper</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HS</Initials>
                    <FamilyName>Lotsof</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GM</Initials>
                    <FamilyName>Frenken</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DJ</Initials>
                    <FamilyName>Luciano</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Bastiaans</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Treatment of acute opioid withdrawal with ibogaine</ArticleTitle>
                  <JournalTitle>Am J Addict</JournalTitle>
                  <VolumeID>8</VolumeID>
                  <FirstPage>234</FirstPage>
                  <LastPage>242</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10506904</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK1Mvjs1OqsA%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1080/105504999305848</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J. Treatment of acute opioid withdrawal with ibogaine.<Emphasis Type="Italic">Am J Addict</Emphasis>. 1999;8:234–242.</BibUnstructured>
              </Citation>
              <Citation ID="CR123">
                <CitationNumber>123.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>O’Hearn</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ME</Initials>
                    <FamilyName>Molliver</FamilyName>
                  </BibAuthorName>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">The olivocerebellar projection mediates ibogaine-induced degeneration of Purkinje cells: a model of indirect, trans-synaptic excitotoxicity</ArticleTitle>
                  <JournalTitle>J Neurosci</JournalTitle>
                  <VolumeID>17</VolumeID>
                  <FirstPage>8828</FirstPage>
                  <LastPage>8841</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9348351</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2sXnsFaltrk%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>O’Hearn E, Molliver ME. The olivocerebellar projection mediates ibogaine-induced degeneration of Purkinje cells: a model of indirect, trans-synaptic excitotoxicity.<Emphasis Type="Italic">J Neurosci</Emphasis>. 1997;17:8828–8841.</BibUnstructured>
              </Citation>
              <Citation ID="CR124">
                <CitationNumber>124.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>UK</Initials>
                    <FamilyName>Bandarage</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ME</Initials>
                    <FamilyName>Kuehne</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SD</Initials>
                    <FamilyName>Glick</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Chemical synthesis and biological evaluation of 18-methoxycoronaridine (18-MC) as a potential anti-addictive agent</ArticleTitle>
                  <JournalTitle>Curr Med Chem CNS Agents</JournalTitle>
                  <VolumeID>1</VolumeID>
                  <FirstPage>113</FirstPage>
                  <LastPage>123</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXlvFWjsbs%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.2174/1568011013354723</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bandarage UK, Kuehne ME, Glick SD. Chemical synthesis and biological evaluation of 18-methoxycoronaridine (18-MC) as a potential anti-addictive agent.<Emphasis Type="Italic">Curr Med Chem CNS Agents</Emphasis>. 2001;1:113–123.</BibUnstructured>
              </Citation>
              <Citation ID="CR125">
                <CitationNumber>125.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>ME</Initials>
                    <FamilyName>Kuehne</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>He</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PA</Initials>
                    <FamilyName>Jokiel</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents</ArticleTitle>
                  <JournalTitle>J Med Chem</JournalTitle>
                  <VolumeID>46</VolumeID>
                  <FirstPage>2716</FirstPage>
                  <LastPage>2730</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12801235</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXjsVOgs70%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1021/jm020562o</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kuehne ME, He L, Jokiel PA, et al. Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents.<Emphasis Type="Italic">J Med Chem</Emphasis>. 2003;46:2716–2730.</BibUnstructured>
              </Citation>
              <Citation ID="CR126">
                <CitationNumber>126.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SD</Initials>
                    <FamilyName>Glick</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>IM</Initials>
                    <FamilyName>Maisonneuve</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KK</Initials>
                    <FamilyName>Szumlinski</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy., toxicity, and mechanisms of action</ArticleTitle>
                  <JournalTitle>Ann NY Acad Sci</JournalTitle>
                  <VolumeID>914</VolumeID>
                  <FirstPage>369</FirstPage>
                  <LastPage>386</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11085336</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXosVakt78%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1749-6632.2000.tb05211.x</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Glick SD, Maisonneuve IM, Szumlinski KK. 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy., toxicity, and mechanisms of action.<Emphasis Type="Italic">Ann NY Acad Sci</Emphasis>. 2000;914:369–386.</BibUnstructured>
              </Citation>
              <Citation ID="CR127">
                <CitationNumber>127.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SD</Initials>
                    <FamilyName>Glick</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>IM</Initials>
                    <FamilyName>Maisonneuve</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HA</Initials>
                    <FamilyName>Dickinson</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">18-MC reduces methamphetamine and nicotine self-administration in rats</ArticleTitle>
                  <JournalTitle>Neuroreport</JournalTitle>
                  <VolumeID>11</VolumeID>
                  <FirstPage>2013</FirstPage>
                  <LastPage>2015</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10884062</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXkslyntbk%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1097/00001756-200006260-00041</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Glick SD, Maisonneuve IM, Dickinson HA. 18-MC reduces methamphetamine and nicotine self-administration in rats.<Emphasis Type="Italic">Neuroreport</Emphasis>. 2000;11:2013–2015.</BibUnstructured>
              </Citation>
              <Citation ID="CR128">
                <CitationNumber>128.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SD</Initials>
                    <FamilyName>Glick</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>IM</Initials>
                    <FamilyName>Maisonneuve</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KK</Initials>
                    <FamilyName>Szumlinski</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener</ArticleTitle>
                  <JournalTitle>Alkaloids Chem Biol</JournalTitle>
                  <VolumeID>56</VolumeID>
                  <FirstPage>39</FirstPage>
                  <LastPage>53</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11705115</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXnsFOls7o%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0099-9598(01)56006-X</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Glick SD, Maisonneuve IM, Szumlinski KK. Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener.<Emphasis Type="Italic">Alkaloids Chem Biol</Emphasis>. 2001;56:39–53.</BibUnstructured>
              </Citation>
              <Citation ID="CR129">
                <CitationNumber>129.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>BL</Initials>
                    <FamilyName>Roth</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Baner</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Westkaemper</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist</ArticleTitle>
                  <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                  <VolumeID>99</VolumeID>
                  <FirstPage>11934</FirstPage>
                  <LastPage>11939</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12192085</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XntFWqtbY%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1073/pnas.182234399</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Roth BL, Baner K, Westkaemper R, et al. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 2002;99:11934–11939.</BibUnstructured>
              </Citation>
              <Citation ID="CR130">
                <CitationNumber>130.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Chavkin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Sud</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W</Initials>
                    <FamilyName>Jin</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Salvinorin A, an active component of the hallucinogenic sage<Emphasis Type="Italic">Salvia divinorum</Emphasis> is a highly efficacious κ-opioid receptor agonist: structural and functional considerations</ArticleTitle>
                  <JournalTitle>J Pharmacol Exp Ther</JournalTitle>
                  <VolumeID>308</VolumeID>
                  <FirstPage>1197</FirstPage>
                  <LastPage>1203</LastPage>
                  <Occurrence Type="PID">
                    <Handle>14718611</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXhvVWnu7k%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1124/jpet.103.059394</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Chavkin C, Sud S, Jin W, et al. Salvinorin A, an active component of the hallucinogenic sage<Emphasis Type="Italic">Salvia divinorum</Emphasis> is a highly efficacious κ-opioid receptor agonist: structural and functional considerations.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2004;308:1197–1203.</BibUnstructured>
              </Citation>
              <Citation ID="CR131">
                <CitationNumber>131.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>ER</Initials>
                    <FamilyName>Butelman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TJ</Initials>
                    <FamilyName>Harris</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MJ</Initials>
                    <FamilyName>Kreek</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys</ArticleTitle>
                  <JournalTitle>Psychopharmacology (Berl)</JournalTitle>
                  <VolumeID>172</VolumeID>
                  <FirstPage>220</FirstPage>
                  <LastPage>224</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXhsFyktLk%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s00213-003-1638-0</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Butelman ER, Harris TJ, Kreek MJ. The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys.<Emphasis Type="Italic">Psychopharmacology (Berl)</Emphasis>. 2004;172:220–224.</BibUnstructured>
              </Citation>
            </Bibliography>
          </ArticleBackmatter>
        </Article>
      </Issue>
    </Volume>
  </Journal>
</Publisher>
